<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<!-- saved from url=(0052)http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/ -->
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
        <!-- AppResources meta begin -->
        <script type="text/javascript">var ncbi_startTime = new Date();</script>
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="">

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="pmc"><meta name="ncbi_pdid" content="article"><meta name="ncbi_acc" content=""><meta name="ncbi_domain" content="wtpa"><meta name="ncbi_report" content="record"><meta name="ncbi_type" content="fulltext"><meta name="ncbi_objectid" content=""><meta name="ncbi_pcid" content="/articles/PMC2722908/"><meta name="ncbi_app" content="pmc">
        <!-- Logger end -->
        
        <title>Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="./PMC2722908_files/jig.min.css"><script type="text/javascript" src="./PMC2722908_files/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE"><link rel="canonical" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/"><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="The New England journal of medicine"><meta name="citation_title" content="Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data"><meta name="citation_authors" content="The International Warfarin Pharmacogenetics Consortium"><meta name="citation_date" content="19 February 2009"><meta name="citation_issue" content="8"><meta name="citation_volume" content="360"><meta name="citation_firstpage" content="753"><meta name="citation_doi" content="10.1056/NEJMoa0809329"><meta name="citation_abstract_html_url" content="/pmc/articles/PMC2722908/?report=abstract"><meta name="citation_pmid" content="19228618"><meta name="DC.Title" content="Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data"><meta name="DC.Type" content="Text"><meta name="DC.Publisher" content="Europe PMC Funders"><meta name="DC.Contributor" content="The International Warfarin Pharmacogenetics Consortium"><meta name="DC.Date" content="2009 Feb 19"><meta name="DC.Identifier" content="10.1056/NEJMoa0809329"><meta name="DC.Language" content="en"><meta property="og:title" content="Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data"><meta property="og:type" content="article"><meta property="og:description" content="Genetic variability among patients plays an important role in determining the dose of warfarin that should be used when oral anticoagulation is initiated, but practical methods of using genetic information have not been evaluated in a diverse and large ..."><meta property="og:url" content="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/"><meta property="og:site_name" content="PubMed Central (PMC)"><meta property="og:image" content="http://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png"><meta name="twitter:card" content="summary"><meta name="twitter:site" content="@ncbi"><link rel="stylesheet" href="./PMC2722908_files/pmc.min.css" type="text/css"><link rel="stylesheet" href="./PMC2722908_files/pmc_extras_prnt.min.css" type="text/css" media="print"><script type="text/javascript" src="./PMC2722908_files/common.min.js">//</script><script type="text/javascript" src="./PMC2722908_files/NcbiTagServer.min.js">//</script><meta name="citationexporter" content="backend:&#39;/pmc/utils/ctxp/&#39;"><script type="text/javascript" src="./PMC2722908_files/jquery.citationexporter.js">//</script><link rel="stylesheet" href="./PMC2722908_files/citationexporter.css" type="text/css"><script type="text/javascript" src="./PMC2722908_files/MathJax.js"></script><script type="text/javascript" src="./PMC2722908_files/large-obj-scrollbars.min.js"></script><script type="text/javascript">window.name="mainwindow";</script><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-wtpa.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style><style type="text/css">
        div.pmc_para_cit li.highlight,
        div.pmc_para_cit li.highlight .one_line_source
        { background: #E0E0E0; }
        a.bibr.highlight { background: #E0E0E0; } 
      </style><link rel="alternate" type="application/epub+zip" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/epub/"><link rel="alternate" type="application/pdf" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/pdf/ukmss-5142.pdf">

        <!-- Page meta end -->
    <link rel="shortcut icon" href="http://www.ncbi.nlm.nih.gov/favicon.ico"><meta name="ncbi_phid" content="8A1A782376C276710000000000644675"><link type="text/css" rel="stylesheet" href="./PMC2722908_files/3855312.css"><link type="text/css" rel="stylesheet" href="./PMC2722908_files/3929378.css" media="print"><style type="text/css" media="print">.print-log { position:absolute;left:-10000px;top:auto;width:1px;height:1px;overflow:hidden; }.print-log li { list-style-image: url('http://www.ncbi.nlm.nih.gov/stat?jsevent=print&ncbi_app=pmc&ncbi_db=pmc&ncbi_pcid=%2Farticles%2FPMC2722908%2F&ncbi_pdid=article&ncbi_phid=8A1A782376C276710000000000644675'); }</style><style type="text/css">.print-log { position:absolute;left:-10000px;top:auto;width:1px;height:1px;overflow:hidden; }</style><style type="text/css">.MathJax_Preview {color: #888}
#MathJax_Message {position: fixed; left: 1em; bottom: 1.5em; background-color: #E6E6E6; border: 1px solid #959595; margin: 0px; padding: 2px 8px; z-index: 102; color: black; font-size: 80%; width: auto; white-space: nowrap}
#MathJax_MSIE_Frame {position: absolute; top: 0; left: 0; width: 0px; z-index: 101; border: 0px; margin: 0px; padding: 0px}
.MathJax_Error {color: #CC0000; font-style: italic}
</style><style type="text/css">.MathJax_Hover_Frame {border-radius: .25em; -webkit-border-radius: .25em; -moz-border-radius: .25em; -khtml-border-radius: .25em; box-shadow: 0px 0px 15px #83A; -webkit-box-shadow: 0px 0px 15px #83A; -moz-box-shadow: 0px 0px 15px #83A; -khtml-box-shadow: 0px 0px 15px #83A; border: 1px solid #A6D ! important; display: inline-block; position: absolute}
.MathJax_Menu_Button .MathJax_Hover_Arrow {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 4px; -webkit-border-radius: 4px; -moz-border-radius: 4px; -khtml-border-radius: 4px; font-family: 'Courier New',Courier; font-size: 9px; color: #F0F0F0}
.MathJax_Menu_Button .MathJax_Hover_Arrow span {display: block; background-color: #AAA; border: 1px solid; border-radius: 3px; line-height: 0; padding: 4px}
.MathJax_Hover_Arrow:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_Hover_Arrow:hover span {background-color: #CCC!important}
</style><style type="text/css">#MathJax_Zoom {position: absolute; background-color: #F0F0F0; overflow: auto; display: block; z-index: 301; padding: .5em; border: 1px solid black; margin: 0; font-weight: normal; font-style: normal; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; -webkit-box-sizing: content-box; -moz-box-sizing: content-box; box-sizing: content-box; box-shadow: 5px 5px 15px #AAAAAA; -webkit-box-shadow: 5px 5px 15px #AAAAAA; -moz-box-shadow: 5px 5px 15px #AAAAAA; -khtml-box-shadow: 5px 5px 15px #AAAAAA; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_ZoomOverlay {position: absolute; left: 0; top: 0; z-index: 300; display: inline-block; width: 100%; height: 100%; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
#MathJax_ZoomFrame {position: relative; display: inline-block; height: 0; width: 0}
#MathJax_ZoomEventTrap {position: absolute; left: 0; top: 0; z-index: 302; display: inline-block; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
</style><style type="text/css">#MathJax_About {position: fixed; left: 50%; width: auto; text-align: center; border: 3px outset; padding: 1em 2em; background-color: #DDDDDD; color: black; cursor: default; font-family: message-box; font-size: 120%; font-style: normal; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 15px; -webkit-border-radius: 15px; -moz-border-radius: 15px; -khtml-border-radius: 15px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_About.MathJax_MousePost {outline: none}
.MathJax_Menu {position: absolute; background-color: white; color: black; width: auto; padding: 5px 0px; border: 1px solid #CCCCCC; margin: 0; cursor: default; font: menu; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 5px; -webkit-border-radius: 5px; -moz-border-radius: 5px; -khtml-border-radius: 5px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
.MathJax_MenuItem {padding: 1px 2em; background: transparent}
.MathJax_MenuArrow {position: absolute; right: .5em; padding-top: .25em; color: #666666; font-size: .75em}
.MathJax_MenuActive .MathJax_MenuArrow {color: white}
.MathJax_MenuArrow.RTL {left: .5em; right: auto}
.MathJax_MenuCheck {position: absolute; left: .7em}
.MathJax_MenuCheck.RTL {right: .7em; left: auto}
.MathJax_MenuRadioCheck {position: absolute; left: .7em}
.MathJax_MenuRadioCheck.RTL {right: .7em; left: auto}
.MathJax_MenuLabel {padding: 1px 2em 3px 1.33em; font-style: italic}
.MathJax_MenuRule {border-top: 1px solid #DDDDDD; margin: 4px 3px}
.MathJax_MenuDisabled {color: GrayText}
.MathJax_MenuActive {background-color: #606872; color: white}
.MathJax_MenuDisabled:focus, .MathJax_MenuLabel:focus {background-color: #E8E8E8}
.MathJax_ContextMenu:focus {outline: none}
.MathJax_ContextMenu .MathJax_MenuItem:focus {outline: none}
#MathJax_AboutClose {top: .2em; right: .2em}
.MathJax_Menu .MathJax_MenuClose {top: -10px; left: -10px}
.MathJax_MenuClose {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; font-family: 'Courier New',Courier; font-size: 24px; color: #F0F0F0}
.MathJax_MenuClose span {display: block; background-color: #AAA; border: 1.5px solid; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; line-height: 0; padding: 8px 0 6px}
.MathJax_MenuClose:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_MenuClose:hover span {background-color: #CCC!important}
.MathJax_MenuClose:hover:focus {outline: none}
</style></head>
    <body class="article" id="ui-jig-5"><div id="MathJax_Message" style="display: none;"></div>
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	&lt;p class="nojs"&gt;
	&lt;strong&gt;Warning:&lt;/strong&gt;
	The NCBI web site requires JavaScript to function. 
	&lt;a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank"&gt;more...&lt;/a&gt;
	&lt;/p&gt;
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list ui-ncbibasicmenu orientation_hort" id="navcontent" role="menubar"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt" role="presentation"><a class="ui-ncbimenu-link-first" href="http://www.ncbi.nlm.nih.gov/" role="menuitem" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="./PMC2722908_files/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo"></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="http://www.ncbi.nlm.nih.gov/static/header_footer_ajax/submenu/#resources" tabindex="-1" role="menuitem">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="http://www.ncbi.nlm.nih.gov/static/header_footer_ajax/submenu/#howto" tabindex="-1" role="menuitem">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="http://www.ncbi.nlm.nih.gov/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="http://www.ncbi.nlm.nih.gov/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="http://www.ncbi.nlm.nih.gov/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="http://www.ncbi.nlm.nih.gov/account/?back_url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2722908%2F" id="sign_in">Sign in to NCBI</a><a href="http://www.ncbi.nlm.nih.gov/account/signout/?back_url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2722908%2F" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo">
  <h1 class="img_logo"><a href="http://www.ncbi.nlm.nih.gov/pmc/" class="pmc_logo offscreen">PMC</a></h1>
  <div class="NLMLogo">
    <a href="http://www.nlm.nih.gov/" title="US National Library of Medicine">US National Library of Medicine</a>
    <br>
    <a href="http://www.nih.gov/" title="National Institutes of Health">National Institutes of Health</a>
  </div>
</div>
    <div class="search"><form method="get" action="http://www.ncbi.nlm.nih.gov/pmc/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="pmc" selected="selected" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="pubmed" class="last">PubMed</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books">Books</option><option value="clinvar">ClinVar</option><option value="clone">Clone</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="nucest">EST</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="nucgss">GSS</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="pubmedhealth">PubMed Health</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbook">ToolKitBook</option><option value="toolkitbookgh">ToolKitBookgh</option><option value="unigene">UniGene</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><div class="ui-ncbiclearbutton-wrap box-shadow"><input type="text" name="term" id="term" title="Search PMC. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" config="dictionary:&#39;pmc-search-autocomplete&#39;,disableUrl:&#39;NcbiSearchBarAutoComplCtrl&#39;" autocomplete="off" data-sbconfig="ds:&#39;no&#39;,pjs:&#39;no&#39;,afs:&#39;yes&#39;" aria-haspopup="true" aria-autocomplete="list" role="textbox"><a class="reset" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#" style="visibility: hidden;"><img src="./PMC2722908_files/clear.png" alt="Clear input"></a></div></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="http://www.ncbi.nlm.nih.gov/pmc/limits/">Limits</a>
                    </li><li>
                        <a href="http://www.ncbi.nlm.nih.gov/pmc/advanced/">Advanced</a>
                    </li><li>
                        <a href="http://www.ncbi.nlm.nih.gov/pmc/journals/">Journal list</a>
                    </li><li class="help">
                        <a target="_blank" href="http://www.ncbi.nlm.nih.gov/books/NBK3825/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <div class="container">
    <div id="maincontent" class="content eight_col col">
        <div class="navlink-box">
            <ul class="page-breadcrumbs inline_list small"><li class="journal-list"><a href="http://www.ncbi.nlm.nih.gov/pmc/journals/" class="navlink">Journal List</a></li><li class="article-entrez-filter"><a href="http://www.ncbi.nlm.nih.gov/pmc/?term=epmc%20author%20manuscript[filter]&amp;cmd=search&amp;EntrezSystem2.PEntrez.Pmc.Pmc_LimitsTab.LimitsOff=true" class="navlink">Europe PMC Author Manuscripts</a></li><li class="accid">PMC2722908</li></ul>
        </div>

        <!-- Journal banner -->
        <div class="pmc-page-banner whole_rhythm"><div><img src="./PMC2722908_files/logo-wtpa2.gif" alt="Logo of wtpa" usemap="#logo-imagemap"><map id="logo-imagemap" name="logo-imagemap"><area shape="rect" coords="395,0,500,52" alt="Europe PMC" title="Europe PMC" href="http://europepmc.org/" ref="reftype=publisher&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=nihms" target="pmc_ext"><area shape="rect" coords="0,0,394,52" alt="Europe PMC Funders Group" title="Europe PMC Funders Group" href="http://europepmc.org/Funders/" ref="reftype=publisher&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=nihms" target="pmc_ext"><area shape="rect" coords="53,0,500,75" alt="Submit a Manuscript" title="Submit a Manuscript" href="https://plus.europepmc.org/" ref="reftype=publisher&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=nihms" target="pmc_ext"></map></div> </div>
        
        <!--component id='MainPortlet' label='search-reference'/-->
        
        <!-- Book content -->
        <div class="">
            
        
            
            <div class="hide-overflow article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: [&#39;h2&#39;], headingExclude: &#39;:hidden&#39;" id="ui-jig-1"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-citation half_rhythm no_top_margin clearfix"><div class="small"><div class="inline_block eight_col va_top"><div>N Engl J Med. Author manuscript; available in PMC 2009 Aug 19.</div><div></div><div>Published in final edited form as:</div><div style="margin-left:1em"><div class="fm-vol-iss-date"><a href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;retmode=ref&amp;cmd=prlinks&amp;id=19228618" target="pmc_ext" ref="reftype=publisher&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CArticle%7CRestricted%20Access&amp;rendering-type=nihms"><span class="cit">N Engl J Med. 2009 Feb 19; 360(8): 753–764. </span></a></div> <span class="doi">doi:&nbsp; <a href="http://dx.doi.org/10.1056%2FNEJMoa0809329" target="pmc_ext" ref="reftype=other&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI&amp;rendering-type=nihms">10.1056/NEJMoa0809329</a></span></div></div><div class="inline_block four_col va_top show-overflow align_right"><div class="fm-citation-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC2722908</span></div><div class="fm-citation-manuscriptid"><span class="fm-citation-ids-label">EMSID: </span><span>UKMS5142</span></div></div></div></div></div><h1 class="content-title">Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data</h1><div class="half_rhythm"><div class="contrib-group fm-author">The International Warfarin Pharmacogenetics Consortium<sup>*</sup></div></div><div class="fm-panel small half_rhythm"><div class="fm-authors-info fm-panel hide half_rhythm" id="id353601_ai" style="display:none"><div class="fm-affl" lang="en"><sup>*</sup>The members of the International Warfarin Pharmacogenetics Consortium are listed in the <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#APP1" rid="APP1" class=" app">Appendix</a>. The members of the writing committee take responsibility for the content of this article.</div><div id="CR1">Address reprint requests to the International Warfarin Pharmacogenetics Consortium at 300 Pasteur Dr., Ln. 301, Mail-stop 5120, Stanford, CA 94305, or at <a href="mailto:dev@null" data-email=".gro.bkgmrahp@cpwi" class="oemail">.gro.bkgmrahp@cpwi</a></div></div><div class="togglers"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#" class="pmctoggle" rid="id353601_ai">Author information <span>►</span></a> <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#" class="pmctoggle" rid="id353601_cpl">Copyright and License information <span>►</span></a></div><div class="fm-article-notes fm-panel half_rhythm"></div><div class="fm-cpl-info fm-panel hide half_rhythm" id="id353601_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="http://www.ncbi.nlm.nih.gov/pmc/about/copyright.html">Copyright notice</a>  and <a href="http://www.ncbi.nlm.nih.gov/About/disclaimer.html">Disclaimer</a></div></div></div><div class="links-box fm-panel whole_rhythm"><div class="small"><div>The publisher's final edited version of this article is available  at <a href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;retmode=ref&amp;cmd=prlinks&amp;id=19228618" target="pmc_ext" ref="reftype=publisher&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CArticle%7CRestricted%20Access&amp;rendering-type=nihms">N Engl J Med</a></div><div><strong>This article has been corrected. </strong>See the correction in volume 361 on&nbsp;page&nbsp;1613.</div><div style="border-top: 1px solid rgb(102, 102, 153); margin: 5px 10% 3px;"></div><div>See other articles in PMC that <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/citedby/">cite</a> the published article.</div></div></div></div><div class="sec"></div><div id="__abstractid648639" lang="en" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-7"><span role="menubar"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#" title="Go to other sections in this page" role="menuitem" aria-expanded="false" aria-haspopup="true" id="ui-jig-8">Go to:</a></span></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__abstractid648639title">Abstract</h2><!--article-meta--><div><div id="S1" class="sec sec-first"><h3>BACKGROUND</h3><p id="P1" class="p p-first-last">Genetic variability among patients plays an important role in determining the dose of warfarin that should be used when oral anticoagulation is initiated, but practical methods of using genetic information have not been evaluated in a diverse and large population. We developed and used an algorithm for estimating the appropriate warfarin dose that is based on both clinical and genetic data from a broad population base.</p></div><div id="S2" class="sec"><h3>METHODS</h3><p id="P2" class="p p-first-last">Clinical and genetic data from 4043 patients were used to create a dose algorithm that was based on clinical variables only and an algorithm in which genetic information was added to the clinical variables. In a validation cohort of 1009 subjects, we evaluated the potential clinical value of each algorithm by calculating the percentage of patients whose predicted dose of warfarin was within 20% of the actual stable therapeutic dose; we also evaluated other clinically relevant indicators.</p></div><div id="S3" class="sec"><h3>RESULTS</h3><p id="P3" class="p p-first-last">In the validation cohort, the pharmacogenetic algorithm accurately identified larger proportions of patients who required 21 mg of warfarin or less per week and of those who required 49 mg or more per week to achieve the target international normalized ratio than did the clinical algorithm (49.4% vs. 33.3%, P&lt;0.001, among patients requiring ≤21 mg per week; and 24.8% vs. 7.2%, P&lt;0.001, among those requiring ≥49 mg per week).</p></div><div id="S4" class="sec sec-last"><h3>CONCLUSIONS</h3><p id="P4" class="p p-first-last">The use of a pharmacogenetic algorithm for estimating the appropriate initial dose of warfarin produces recommendations that are significantly closer to the required stable therapeutic dose than those derived from a clinical algorithm or a fixed-dose approach. The greatest benefits were observed in the 46.2% of the population that required 21 mg or less of warfarin per week or 49 mg or more per week for therapeutic anticoagulation.</p></div></div></div><div id="__bodyid1401787" class="tsec sec headless whole_rhythm"><p id="P5" class="p p-first">Warfarin is the most widely used oral anticoagulant agent worldwide; more than 30 million prescriptions were written for this drug in the United States in 2004.<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R1" rid="R1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_288582875" role="button" aria-expanded="false" aria-haspopup="true">1</a></sup> The appropriate dose of warfarin is difficult to establish because it can vary by a factor of 10 among patients, and the consequences of taking an incorrect dose can be catastrophic. Because incorrect doses contribute to a high rate of adverse effects, there is interest in developing improved strategies for determining the appropriate dose.<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R2" rid="R2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_288582895" role="button" aria-expanded="false" aria-haspopup="true">2</a></sup></p><p id="P6" class="p">Clinical factors, demographic variables, and variations in two genes — cytochrome P450, family 2, subfamily C, polypeptide 9 (<em>CYP2C9</em>), and vitamin K epoxide reductase complex, subunit 1 (<em>VKORC1</em>) — contribute significantly to the variability among patients in dose requirements for warfarin.<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R3" rid="R3" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_288582896" role="button" aria-expanded="false" aria-haspopup="true">3</a></sup><sup>-</sup><sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R18" rid="R18" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_288582889" role="button" aria-expanded="false" aria-haspopup="true">18</a></sup> In 2007, the Food and Drug Administration added pharmacogenetic information to the warfarin product label<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R19" rid="R19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_288582883" role="button" aria-expanded="false" aria-haspopup="true">19</a></sup> but did not propose a specific method for using genetic information to predict the dose required in individual patients. Proposed algorithms for predicting the appropriate dose of warfarin<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R3" rid="R3" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_288582898" role="button" aria-expanded="false" aria-haspopup="true">3</a></sup><sup>,</sup><sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R5" rid="R5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_288582894" role="button" aria-expanded="false" aria-haspopup="true">5</a></sup><sup>,</sup><sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R9" rid="R9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_288582900" role="button" aria-expanded="false" aria-haspopup="true">9</a></sup><sup>,</sup><sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R13" rid="R13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_288582885" role="button" aria-expanded="false" aria-haspopup="true">13</a></sup><sup>,</sup><sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R18" rid="R18" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_288582879" role="button" aria-expanded="false" aria-haspopup="true">18</a></sup><sup>,</sup><sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R20" rid="R20" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_288582893" role="button" aria-expanded="false" aria-haspopup="true">20</a></sup> are usually based on relatively small clinical populations, and their general predictive accuracy is uncertain.<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R21" rid="R21" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_288582891" role="button" aria-expanded="false" aria-haspopup="true">21</a></sup> Small trials have recently been performed<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R3" rid="R3" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_288582890" role="button" aria-expanded="false" aria-haspopup="true">3</a></sup><sup>,</sup><sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R22" rid="R22" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_288582888" role="button" aria-expanded="false" aria-haspopup="true">22</a></sup> and large, prospective trials are ongoing or planned in the United States<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R23" rid="R23" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_288582897" role="button" aria-expanded="false" aria-haspopup="true">23</a></sup> and Europe to test whether algorithms for warfarin dosage that use genetic information improve the outcomes for patients (e.g., better anticoagulation control and a shorter time to achieving a stable dose). We developed a pharmacogenetic dose algorithm for warfarin with the use of a large and diverse data set that included data from patients at centers around the world and used it to determine retrospectively whether the dosage recommendations that were based on this algorithm were significantly better than those that were based on an algorithm that used only clinical variables or those that were based on a fixed-dose strategy.</p></div><div id="S5" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-9"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-10">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S5title">METHODS</h2><div id="S6" class="sec sec-first"><h3>DATA COLLECTION AND STUDY COHORTS</h3><p id="P7" class="p p-first">The International Warfarin Pharmacogenetics Consortium comprises 21 research groups from 9 countries and 4 continents. The research groups contributed clinical and genetic data for a total of 5700 patients who were treated with warfarin. These data were curated (i.e., collected, formatted, and subjected to quality control) by staff at the Pharmacogenetics and Pharmacogenomics Knowledge Base (PharmGKB, <a href="http://www.pharmgkb.org/" ref="reftype=extlink&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI&amp;rendering-type=nihms" target="pmc_ext">www.pharmgkb.org</a>) and by members of the consortium. The cohort whose data were analyzed for this study included the subgroup of 5052 patients who had a target international normalized ratio (INR) of 2 to 3. The requirement for informed consent was waived because consent had been obtained previously by each participating center, and only de-identified data were used in the study.</p><p id="P8" class="p p-last">We collected data on clinical factors that have previously been associated with warfarin therapy and that were available from the information received from all or most sites. These data included information on demographic characteristics, the primary indication for warfarin treatment, the stable therapeutic dose of warfarin, the treatment INR (the INR achieved with a stable warfarin dose), the target INR (the desired INR), the use of concomitant medications (grouped according to those that increase and those that decrease the INR), and the presence of genotype variants of <em>CYP2C9</em> (*1, *2 and *3) and <em>VKORC1</em> (at least one of seven single nucleotide polymorphisms [SNPs] in linkage disequilibrium<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R11" rid="R11" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_288582886" role="button" aria-expanded="false" aria-haspopup="true">11</a></sup>), as detailed in Section 1 in <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#SD1" rid="SD1" class=" supplementary-material">Supplementary Appendix 1</a>, available with the full text of this article at <a href="http://nejm.org/" ref="reftype=extlink&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI&amp;rendering-type=nihms" target="pmc_ext">NEJM.org</a>. Information on race or ethnic group was reported by the patient or determined by the local investigator. Several potentially important variables (e.g., vitamin K intake and smoking status) were not consistently available and thus were not included. Data on adverse events such as thromboembolic events or bleeding or the need for repeated measurements of the INR before a stable dose was achieved were not available for this study. The outcome variable was the stable therapeutic dose of warfarin, defined as the steady-state dose that led to stable anticoagulation levels. Although the centers used different definitions for steady-state dose, most centers required stable levels of anticoagulation (i.e., INR) over a period during which the dose of warfarin was stable (Section 2 in <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#SD1" rid="SD1" class=" supplementary-material">Supplementary Appendix 1</a>).</p></div><div id="S7" class="sec"><h3>GENOTYPE QUALITY CONTROL</h3><p id="P9" class="p p-first-last">The National Genotyping Center at the Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan, performed blinded regenotyping for quality control on DNA samples from 10% of the subjects from each site (except for sites 3, 9, and 14, which could not ship DNA samples internationally). DNA samples that were used for quality control were genotyped for the two polymorphisms in <em>CYP2C9</em> (*2=rs1799853, and *3=rs1057910) and seven SNPs in <em>VKORC1</em> (−1639 G→A=rs9923231, 1173 C→T=rs9934438, 497 T→G=rs2884737, 1542 G→C=rs8050894, 3730 G→A=rs7294, 2255 C→T=rs2359612, −4451 C→A=rs17880887). <em>CYP2C9</em> *2 and *3 and <em>VKORC1</em> rs9923231 were genotyped with the use of the TaqMan allelic discrimination assay (Applied Biosystems), whereas the remaining <em>VKORC1</em> SNPs were genotyped by mass spectrometry with the use of MassARRAY (Sequenom). Both methods had been validated previously at the National Genotyping Center with the use of direct sequencing and denaturing high-performance liquid chromatography, with 100% concordance on 200 samples. The complete data set of genotypes and clinical variables, as well as the full genotype quality-control data, is available to registered PharmGKB users at <a href="http://www.pharmgkb.org/" ref="reftype=extlink&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI&amp;rendering-type=nihms" target="pmc_ext">www.pharmgkb.org</a> (full data set accession number, PA162355460).</p></div><div id="S8" class="sec sec-last"><h3>STATISTICAL ANALYSIS</h3><p id="P10" class="p p-first">We randomly chose 80% of the eligible patients, (stratified according to site, for a total of 4043 patients who had a stable dose of warfarin and a target INR of 2 to 3) as the “derivation cohort” for developing all dose-prediction models. The remaining 20% of the patients (1009 patients, from all 21 sites) constituted the “validation cohort,” which was used for testing the final selected model. The investigators who performed the modeling and analysis did not have access to this validation set until after the final model was selected. A wide variety of numerical modeling methods were used for the data from the derivation cohort, including, but not limited to, support vector regression, regression trees, model trees, multivariate adaptive regression splines, least-angle regression, and Lasso, in addition to ordinary linear regression. Logarithmic and square-root transformations of doses were tested, in addition to a direct prediction of dose. Further details of the statistical modeling approaches that were tested and the evaluation methods that were used for selecting the best model from the derivation cohort are described in Section 3 in <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#SD1" rid="SD1" class=" supplementary-material">Supplementary Appendix 1</a>.</p><p id="P11">Missing values for the <em>VKORC1</em> SNP rs9923231 were imputed on the basis of race and on the basis of the <em>VKORC1</em> SNP data at rs2359612, rs9934438, or rs8050894 (see Section 4 in <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#SD1" rid="SD1" class=" supplementary-material">Supplementary Appendix 1</a>). If the <em>VKORC1</em> genotype could not be imputed, it was treated as “missing” (a distinct variable) in the model.</p><p id="P12">The mean absolute error — that is, the mean of the absolute values for the difference between the predicted and actual maintenance doses — was used to evaluate each model's predictive accuracy. For models developed with the use of transformed data, the mean absolute error was computed in the original units rather than in the transformed units to allow a fair comparison of all models. We selected the final model as the one that had the lowest predictive mean absolute error as estimated by 10-fold cross-validation on the derivation cohort (detailed in Section 3 in <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#SD1" rid="SD1" class=" supplementary-material">Supplementary Appendix 1</a>). Using the validation data set, we compared dose predictions from the pharmacogenetic model with those from two other models: a clinical model that did not include genetic factors and a model with a fixed dose of 5 mg of warfarin per day. The clinical model was built with the use of the same methods as the pharmacogenetic model, but without the incorporation of genetic variables. The following assessment of clinical significance is based on this validation data set except where otherwise stated.</p><p id="P13" class="p p-last">The mean absolute error and the coefficient of determination (R<sup>2</sup>) in the validation data set were our prespecified metrics for evaluating the pharmacogenetic, clinical, and fixed-dose models. These models were selected before the metrics were computed; thus, there were no multiple comparisons. We evaluated the potential clinical value of each algorithm by calculating the percentage of patients whose predicted dose of warfarin was within 20% of the actual stable therapeutic dose. In addition, we calculated the percentage of patients for whom the predicted dose according to each algorithm was at least 20% higher than the actual dose (overestimation) or at least 20% lower than the actual dose (underestimation). These values represent a difference of 1 mg per day relative to the traditional starting dose of 5 mg per day, a difference clinicians would be likely to define as clinically relevant. We also assessed the performance of the algorithms in three dose groups: participants requiring a low dose (≤21 mg per week), those requiring a high dose (≥49 mg per week), and those requiring intermediate doses (&gt;21 and &lt;49 mg per week) for stable therapeutic anticoagulation. These thresholds of 21 mg and 49 mg per week bracket the usual starting dose of 35 mg per week (5 mg per day). Patients requiring doses of less than 21 mg per week would be at risk for excessive anticoagulation if they were started on the standard dose of 35 mg per week. Conversely, patients requiring doses of more than 49 mg per week would be at risk for inadequate anticoagulation if they were started on a dose of 35 mg per week. We performed sensitivity analyses using other dose thresholds as well (see Section 5 in <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#SD1" rid="SD1" class=" supplementary-material">Supplementary Appendix 1</a>). We assessed the potential benefit of using the pharmacogenetic algorithm instead of the clinical algorithm or the fixed-dose model and computed the number needed to genotype (i.e., the number of patients who must be genotyped in order for one patient to have an improved dose estimate).<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R24" rid="R24" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_288582877" role="button" aria-expanded="false" aria-haspopup="true">24</a></sup> Finally, in a post hoc analysis, we assessed how well the algorithms predicted which patients actually required low or high doses.</p></div></div><div id="S9" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-11"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-12">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S9title">RESULTS</h2><div id="S10" class="sec sec-first"><h3>CHARACTERISTICS OF THE PATIENTS AND QUALITY OF GENOTYPING DATA</h3><p id="P14" class="p p-first-last">The characteristics of the patients are shown in <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/table/T1/" target="true" class="fig-table-link table figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>. Genotype quality control was conducted on 480 samples (8.4% of the data set). The overall concordance for <em>CYP2C9</em> SNPs in the genotype quality control was 97.8%, and the overall concordance for <em>VKORC1</em> SNPs was 97.7%. Exclusion of the three sites that did not participate in the quality-control genotyping did not change the model. Each SNP was in Hardy–Weinberg equilibrium when it was tested in patients who were stratified according to race.</p><!--table ft1--><!--table-wrap mode=article t1--><div class="table-wrap iconblock ten_col whole_rhythm clearfix" id="T1"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/table/T1/" target="table" rid-ob="ob-T1" rid-figpopup="T1" class="table img_link icnblk_img figpopup"><img alt="Table 1" title="Table 1" class="small-thumb" src="./PMC2722908_files/saved_resource" src-large="/pmc/articles/PMC2722908/table/T1/?report=previmg"></a><div class="icnblk_cntnt"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/table/T1/" target="table" rid-figpopup="T1" rid-ob="ob-T1">Table 1</a></div><!--caption a4--><div><span>Demographic and Clinical Characteristics of the Derivation and Validation Cohorts</span></div></div></div></div><div id="S11" class="sec"><h3>MODELING APPROACHES</h3><p id="P15" class="p p-first-last">An ordinary least-squares linear regression modeling method to develop a pharmacogenetic algorithm that predicts the square root of the dose and incorporates both genetic and clinical data proved to be the best modeling approach for these data (see Section 3 in <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#SD1" rid="SD1" class=" supplementary-material">Supplementary Appendix 1</a>; the actual model is shown in Section 1 in <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#SD1" rid="SD1" class=" supplementary-material">Supplementary Appendix 1</a>). This approach performed best according to our criterion of the lowest mean absolute error but would also have been selected if the criterion had been the lowest root mean squared error. Although it may be somewhat surprising that ordinary least-squares regression would perform best according to the mean absolute error, the reason, in part, appears to be that minimizing the squared error in the prediction of the square root of the dose effectively minimizes the mean absolute error. This strong performance of ordinary least-squares regression was fortuitous because it yielded a simpler and more easily understood model than many of the more complex modeling approaches we used. Because the resulting dose algorithm computes the square root of the weekly dose, the output must be squared to compute the weekly dose. This algorithm is available at <a href="http://www.warfarindosing.org/" ref="reftype=extlink&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI&amp;rendering-type=nihms" target="pmc_ext">www.warfarindosing.org</a> and as a Microsoft Excel workbook (see <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#SD2" rid="SD2" class=" supplementary-material">Supplementary Appendix 2</a> and Section 6 in <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#SD1" rid="SD1" class=" supplementary-material">Supplementary Appendix 1</a>). With the use of the same linear regression approach, we also constructed an algorithm that included clinical variables only, with no incorporation of genetic data (see Section 1 in <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#SD1" rid="SD1" class=" supplementary-material">Supplementary Appendix 1</a>).</p></div><div id="S12" class="sec"><h3>DOSES PREDICTED BY THE THREE MODELS</h3><p id="P16" class="p p-first">The performance of the pharmacogenetic, clinical, and fixed-dose models in the derivation and validation cohorts is shown in <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/table/T2/" target="true" class="fig-table-link table figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a>. The pharmacogenetic algorithm provided dose estimates that were significantly closer to the actual doses required than the estimates derived from the clinical algorithm or the fixed-dose approach, as evidenced by a mean absolute error that was lower than that for both the clinical algorithm and the fixed-dose approach (8.5±1.7 mg per week vs. 9.9±1.9 mg per week and 13.0±2.3 mg per week, respectively; P&lt;0.001 for both comparisons). <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/figure/F1/" target="figure" class="fig-table-link fig figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1</span></a> shows comparisons of the predicted doses according to representative clinical or demographic characteristics, genotype combinations, race, and use or nonuse of amiodarone (an important interacting drug). These data show the way in which the addition of genetic information altered the dose prediction from the clinical model and suggest that most of the racial differences in dose requirements are explained by genotype. The addition of genetic information to clinical information decreased the absolute error in the dose estimate and increased the fraction of variability explained (R<sup>2</sup>). The R<sup>2</sup> values and the P values for each factor in the two models are shown in Section 7 in <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#SD1" rid="SD1" class=" supplementary-material">Supplementary Appendix 1</a>; a graph of the predicted warfarin dose based on the pharmacogenetic algorithm as compared with the observed dose in the validation cohort is shown in Section 8 in <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#SD1" rid="SD1" class=" supplementary-material">Supplementary Appendix 1</a>.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock ten_col whole_rhythm clearfix" id="F1" co-legend-rid="lgnd_F1"><a class="icnblk_img figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1"><img src="./PMC2722908_files/ukmss-5142-f0001.gif" class="small-thumb" alt="Figure 1" title="Figure 1" src-large="/pmc/articles/PMC2722908/bin/ukmss-5142-f0001.jpg"></a><div class="icnblk_cntnt" id="lgnd_F1"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1">Figure 1</a></div><!--caption a4--><div><span><!--caption a8--><strong>Comparisons of Warfarin Doses Predicted According to the Clinical Algorithm and the Pharmacogenetic Algorithm</strong></span></div></div></div><!--table ft1--><!--table-wrap mode=article t1--><div class="table-wrap iconblock ten_col whole_rhythm clearfix" id="T2"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/table/T2/" target="table" rid-ob="ob-T2" rid-figpopup="T2" class="table img_link icnblk_img figpopup"><img alt="Table 2" title="Table 2" class="small-thumb" src="./PMC2722908_files/saved_resource(1)" src-large="/pmc/articles/PMC2722908/table/T2/?report=previmg"></a><div class="icnblk_cntnt"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/table/T2/" target="table" rid-figpopup="T2" rid-ob="ob-T2">Table 2</a></div><!--caption a4--><div><span>Predicted Warfarin Doses with the Pharmacogenetic Algorithm, Clinical Algorithm, and Fixed-Dose Approach as Compared with the Actual Stable Dose in the Derivation and Validation Cohorts.<sup>*</sup></span></div></div></div><p id="P17" class="p p-last">We also derived specific models for different racial and ethnic groups, but in all cases, the general model that was adjusted for race performed better than these specific models. The performance at individual centers reflected the racial and ethnic makeup of the local patient population, with no influential outliers, a finding that was consistent with the genotype quality-control data. The pharmacogenetic model performed well for each of the three major ethnic groups and for each of the 21 sites (Section 9 in <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#SD1" rid="SD1" class=" supplementary-material">Supplementary Appendix 1</a>).</p></div><div id="S13" class="sec sec-last"><h3>CLINICAL RELEVANCE</h3><p id="P18" class="p p-first">The pharmacogenetic algorithm provided more accurate dose estimates than the clinical algorithm or the fixed-dose approach (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/table/T2/" target="true" class="fig-table-link table figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a>). The differences in the performance of the three approaches in the low-dose (≤21 mg per week), intermediate-dose (&gt;21 and &lt;49 mg per week), and high-dose (≥49 mg per week) groups are shown in <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/figure/F2/" target="figure" class="fig-table-link fig figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Figure 2</span></a> and <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/table/T3/" target="true" class="fig-table-link table figpopup" rid-figpopup="T3" rid-ob="ob-T3" co-legend-rid=""><span>Table 3</span></a>. For patients who required 21 mg or less of warfarin per week (33.9% of the total cohort), the pharmacogenetic algorithm provided a significantly better prediction of dose than the clinical algorithm or the fixed-dose approach; 35% of the dose predictions fell within 20% of the actual dose (“ideal dose”) with the pharmacogenetic algorithm as compared with 24% with the clinical algorithm (P&lt;0.001) and 0% with the fixed-dose approach (P&lt;0.001). In addition, the pharmacogenetic algorithm provided significantly fewer overestimations of dose in the low-dose group (59.7%, vs. 74.8% with the clinical algorithm [P&lt;0.001]; and 100% with the fixed-dose approach [P&lt;0.001]) (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/table/T3/" target="true" class="fig-table-link table figpopup" rid-figpopup="T3" rid-ob="ob-T3" co-legend-rid=""><span>Table 3</span></a>). Similarly, for patients requiring 49 mg or more per week (12.4% of the total cohort), the pharmacogenetic algorithm predicted doses in the ideal range for significantly more patients than did the clinical algorithm or the fixed-dose approach (32.8% vs. 13.3% and 0%, respectively; P&lt;0.001 for both comparisons), with significantly fewer dose underestimations (66.7% vs. 86.2% and 100%, respectively; P&lt;0.001 for both comparisons). In the intermediate-dose group, the accuracy of the dose prediction was similar with the three approaches. A sensitivity analysis that used different dose thresholds (Section 5 in <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#SD1" rid="SD1" class=" supplementary-material">Supplementary Appendix 1</a>) highlighted the fact that the pharmacogenetic algorithm provided consistently better dose prediction. <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/table/T4/" target="true" class="fig-table-link table figpopup" rid-figpopup="T4" rid-ob="ob-T4" co-legend-rid=""><span>Table 4</span></a> shows the comparison of the pharmacogenetic and clinical algorithms with respect to dose prediction for patients who required low or high doses — an important feature for clinicians when they are initiating treatment. Specifically, for the overall cohort, the pharmacogenetic algorithm correctly predicted low doses for 54% of all patients who required low doses, as compared with the clinical algorithm, which predicted low doses for 33% of these patients (P&lt;0.001). Similarly, the pharmacogenetic algorithm accurately predicted high doses for 26% of patients who required high doses, as compared with the clinical algorithm, which predicted high doses for 9% of these patients (P&lt;0.001). Thus, the pharmacogenetic algorithm significantly improved the dose prediction for patients who required either high or low doses of warfarin, a group that accounted for 46% of the entire cohort.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock ten_col whole_rhythm clearfix" id="F2" co-legend-rid="lgnd_F2"><a class="icnblk_img figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2"><img src="./PMC2722908_files/ukmss-5142-f0002.gif" class="small-thumb" alt="Figure 2" title="Figure 2" src-large="/pmc/articles/PMC2722908/bin/ukmss-5142-f0002.jpg"></a><div class="icnblk_cntnt" id="lgnd_F2"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2">Figure 2</a></div><!--caption a4--><div><span><!--caption a8--><strong>Percentage of Patients with Dose Estimates within 20% of the Actual Dose, as Derived with the Use of a Pharmacogenetic Algorithm, a Clinical Algorithm, and a Fixed-Dose Approach</strong></span></div></div></div><!--table ft1--><!--table-wrap mode=article t1--><div class="table-wrap iconblock ten_col whole_rhythm clearfix" id="T3"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/table/T3/" target="table" rid-ob="ob-T3" rid-figpopup="T3" class="table img_link icnblk_img figpopup"><img alt="Table 3" title="Table 3" class="small-thumb" src="./PMC2722908_files/saved_resource(2)" src-large="/pmc/articles/PMC2722908/table/T3/?report=previmg"></a><div class="icnblk_cntnt"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/table/T3/" target="table" rid-figpopup="T3" rid-ob="ob-T3">Table 3</a></div><!--caption a4--><div><span>Percentage of Patients in the Validation Cohort and in the Derivation-plus-Validation Cohort with an Ideal, Underestimated, or Overestimated Dose of Warfarin, as Estimated with the Pharmacogenetic Algorithm, Clinical Algorithm, and Fixed-Dose Approach</span> <strong>...</strong></div></div></div><!--table ft1--><!--table-wrap mode=article t1--><div class="table-wrap iconblock ten_col whole_rhythm clearfix" id="T4"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/table/T4/" target="table" rid-ob="ob-T4" rid-figpopup="T4" class="table img_link icnblk_img figpopup"><img alt="Table 4" title="Table 4" class="small-thumb" src="./PMC2722908_files/saved_resource(3)" src-large="/pmc/articles/PMC2722908/table/T4/?report=previmg"></a><div class="icnblk_cntnt"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/table/T4/" target="table" rid-figpopup="T4" rid-ob="ob-T4">Table 4</a></div><!--caption a4--><div><span>Ability of the Pharmacogenetic and Clinical Algorithms to Correctly Identify Patients Requiring Low or High Doses of Warfarin.</span></div></div></div><p id="P19" class="p p-last">Overall, estimates of dose derived with the use of the pharmacogenetic algorithm were closer to the actual dose than were estimates derived from the clinical algorithm for 60% of the patients and were closer than the fixed dose for 69% of the patients. To estimate the potential for a clinically meaningful improvement in dose prediction, we assessed the number of patients for whom one algorithm estimated a dose within 20% of the actual dose and the other algorithm did not — a stricter standard than simply the proximity to the actual dose. For the entire cohort, the number of patients needed to genotype in order to obtain such an improvement with the pharmacogenetic algorithm in one patient was 13.2 for the comparison with the clinical algorithm and 6.0 for the comparison with a fixed dose of 35 mg per week (Section 10 in <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#SD1" rid="SD1" class=" supplementary-material">Supplementary Appendix 1</a>).</p></div></div><div id="S14" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-13"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-14">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S14title">DISCUSSION</h2><p id="P20" class="p p-first">The pharmacogenetic algorithm we developed provided significantly better predictions of the appropriate dose of warfarin than either the clinical algorithm or a fixed-dose approach. The greatest differences among the dose-prediction approaches were noted among patients whose stable therapeutic warfarin doses were 21 mg or less per week and among those whose stable doses were 49 mg or more per week, representing 46% of the cohort. These are the patients for whom an underdose or an overdose could have adverse clinical consequences. Patients who require intermediate doses are likely to obtain little benefit from the use of a pharmacogenetic algorithm.</p><p id="P21">Our analysis does not address the issue of whether a precise initial dose of warfarin translates into improved clinical end points, such as a reduction in the time needed to achieve a stable therapeutic INR, fewer INRs that are out of range, and a reduced incidence of bleeding or thromboembolic events. However, our study lays important groundwork for a prospective trial and suggests that such a trial should be powered to detect the benefits of incorporating pharmacogenetic information into the dose algorithm for patients who require high or low doses — the subgroups in our study for whom dose estimates based on the pharmacogenetic algorithm differed significantly from those based on the clinical algorithm.</p><p id="P22">Visual inspection of the graph of pharmacogenetic dose prediction as compared with actual warfarin dose (Section 8 in <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#SD1" rid="SD1" class=" supplementary-material">Supplementary Appendix 1</a>) suggests that the pharmacogenetic algorithm performed less predictably among patients who required very high doses of warfarin (&gt;70 mg per week). The common genetic markers explored in our study primarily explain increased sensitivity to warfarin, not increased resistance. Mutations of <em>VKORC1</em> have been associated with resistance to warfarin, but these mutations are rare except in Ethiopian and certain Jewish populations.<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R19" rid="R19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_288582887" role="button" aria-expanded="false" aria-haspopup="true">19</a></sup><sup>,</sup><sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R25" rid="R25" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">25</a></sup><sup>-</sup><sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R28" rid="R28" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_288582878" role="button" aria-expanded="false" aria-haspopup="true">28</a></sup> The discovery of additional genes (e.g., through genomewide association studies) may identify additional genetic variants that can improve predictability in patients who require high doses of warfarin.</p><p id="P23">Our study has other limitations. First, we did not have sufficient data across the 21 research groups to include potentially important factors such as smoking status, vitamin K intake, or alcohol consumption, as well as other genetic factors (e.g., cytochrome P450, family 4, subfamily F, polypeptide 2 [<em>CYP4F2</em>], apolipoprotein E [<em>ApoE</em>], or gamma-glutamyl carboxylase [<em>GGCX</em>])<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R4" rid="R4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_288582884" role="button" aria-expanded="false" aria-haspopup="true">4</a></sup><sup>,</sup><sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R5" rid="R5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_288582882" role="button" aria-expanded="false" aria-haspopup="true">5</a></sup><sup>,</sup><sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R16" rid="R16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_288582901" role="button" aria-expanded="false" aria-haspopup="true">16</a></sup><sup>,</sup><sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R17" rid="R17" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_288582892" role="button" aria-expanded="false" aria-haspopup="true">17</a></sup><sup>,</sup><sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R29" rid="R29" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_288582881" role="button" aria-expanded="false" aria-haspopup="true">29</a></sup><sup>-</sup><sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R31" rid="R31" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_288582876" role="button" aria-expanded="false" aria-haspopup="true">31</a></sup> or environmental factors<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R32" rid="R32" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_288582899" role="button" aria-expanded="false" aria-haspopup="true">32</a></sup> that could help predict the stable therapeutic dose of warfarin. However, the percentage of dose variability among patients that is explained by our model is similar to that in other published models, so the effect of these variables is probably small. Second, we did not have any information about adverse events that may have occurred before stable anticoagulation was achieved; our data set provided only the eventual stable therapeutic doses. Third, different sites genotyped different subgroups of <em>VKORC1</em> SNPs, requiring us to impute missing genotypes for some patients. Our imputation strategy, which is based on linkage disequilibrium in <em>VKORC1,</em> is generally reliable (see Section 4 in <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#SD1" rid="SD1" class=" supplementary-material">Supplementary Appendix 1</a>),<sup><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R11" rid="R11" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_288582880" role="button" aria-expanded="false" aria-haspopup="true">11</a></sup> but it may have introduced some error; however, the error would probably have led to an underestimation of the benefit of adding genetic information. We also restricted our algorithm to patients who had a target INR of 2 to 3, so it provides no explicit guidance on dosage to achieve INRs outside this range. The population included in this study represents the typical population that is treated with warfarin — namely, the elderly. Only 6% of the cohort was younger than 40 years of age; therefore, additional research with respect to the use of these algorithms in children and younger adults is needed.</p><p id="P24" class="p p-last">In conclusion, using data from a large and diverse cohort of patients, we developed a pharmacogenetic dose algorithm for warfarin that uses genotypes from two genes (<em>VKORC1</em> and <em>CYP2C9</em>) and clinical variables to predict the stable therapeutic dose. This pharmacogenetic algorithm predicts the stable therapeutic dose of warfarin better than a fixed-dose approach and better than a clinical algorithm built from the same large data set. With the use of this algorithm and a definition of the ideal estimated dose as a dose that differs by no more than 20% from the stable dose, the pharmacogenetic algorithm produced significantly better dose estimates, with the greatest benefit seen in patients ultimately requiring 21 mg or less of warfarin per week and in those requiring 49 mg or more per week. The pharmacogenetic algorithm thus provides a robust basis for a prospective clinical trial of the efficacy of genetically informed dose estimation for patients who require warfarin.</p></div><div id="SM" class="tsec sec"><a id="supplementary-material-sec"></a><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-15"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-16">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="SMtitle">Supplementary Material</h2><!--/article/body/sec/--><div class="sec suppmat" id="SD1"><h4>Supplementary appendix 1</h4><div class="sup-box half_rhythm" id="d35e443"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/bin/NIHMS5142-supplement-Supplementary_appendix_1.pdf">Click here to view.</a><sup>(455K, pdf)</sup></div></div><div class="sec suppmat" id="SD2"><h4>Supplementary appendix 2</h4><div class="sup-box half_rhythm" id="d35e447"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/bin/NIHMS5142-supplement-Supplementary_appendix_2.xls">Click here to view.</a><sup>(14K, xls)</sup></div></div></div><div id="S15" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-17"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-18">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="S15title">Acknowledgments</h2><div class="sec"><p id="__p1">Supported by grants from the National Institutes of Health Pharmacogenetics Research Network (GM61374, GM074492, GM63340, and HL65962); National Institute of General Medical Sciences (GM68797 and GM32165); National Heart, Lung, and Blood Institute (HL092173, HL068834, HL066176, HL070936, HL074724, and HL71083); National Institute of Neurological Disorders and Stroke (NS45598 and NS053646); National Center for Research Resources (RR020741); National Research Program for Genomic Medicine, National Science Council, Taiwan (NSC95-3112-B-001-010 and NSC95-3112-B-001-011); Israeli Science Foundation (789/04); United States–Israel Binational Foundation (2003229); Ministry of Health, Korea (5745); Korea Science and Engineering Foundation and Korean Ministry of Education, Science, and Engineering (R13-2007-023-00000-0); Korea Health 21 Research and Development Project, Korean Ministry of Health and Welfare (A030001); Conselho Nacional de Desenvolvimento Científico e Tecnológico; Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro; Financiadora de Estudos e Projetos; National Health Service Executive (Northern and Yorkshire); American Association of Colleges of Pharmacy; American Foundation for Pharmaceutical Education; American Heart Association; United Kingdom Department of Health; North Carolina Biotechnology Company (Multidisciplinary Research Grant 2006-MRG-1117); Leading Project of Ministry of Education, Culture, Sports, Science, and Technology, Japan; Centers for Disease Control and Prevention National Office of Public Health Genomics Seed Funding; University of Washington Drug Metabolism, Transport, and Pharmacogenomics Research Program; Swedish Society of Medicine; Foundation for Strategic Research, Sweden; Heart and Lung Foundation, Sweden; Söderberg, Thuréus, and Selander Foundations, Sweden; Clinical Research Support (Avtal om läkarutbildning och forskning), Sweden; and the Wellcome Trust, United Kingdom.</p><p id="__p2">Dr. Klein reports receiving consulting fees from Affymetrix; Dr. Gage, receiving grant support from Osmetech; Dr. Altman, receiving consulting fees from and holding equity in 23andMe; Dr. Kimmel, receiving consulting fees from Pfizer, GlaxoSmithKline, Novartis, and Centocor and grant support from the Aetna Foundation, Shire, and Pfizer; Dr. Limdi, receiving grant support from UCB; Dr. Johnson, receiving consulting fees from Medco; and Dr. Caldwell, being a named coinventor on the Marshfield Clinic provisional patent (application number 60981186) on the association of polymorphisms in CYP4F2 with the stable therapeutic dose of warfarin (a patent that has been licensed by the Marshfield Clinic to Osmetech Molecular Diagnostics). No other potential conflict of interest relevant to this article was reported.</p><p id="__p3">The complete data set of genotypes and clinical variables, as well as the full genotype quality-control data, is available to registered PharmGKB users at <a href="http://www.pharmgkb.org/" ref="reftype=extlink&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI&amp;rendering-type=nihms" target="pmc_ext">www.pharmgkb.org</a> (full data set accession number, PA162355460).</p></div></div><div id="APP1" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-19"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-20">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="APP1title">APPENDIX</h2><!--/article/back/app-group/app/--><p id="P25">The members of the International Warfarin Pharmacogenetics Consortium are as follows (alphabetical listing by institution): <strong>Writing Committee</strong> — T.E. Klein, R.B. Altman, N. Eriksson, B.F. Gage, S.E. Kimmel, M.-T.M. Lee, N.A. Limdi, D. Page, D.M. Roden, M.J. Wagner, M.D. Caldwell, J.A. Johnson; <strong>Data Contributors</strong> — <em>Academic Sinica, Taipei, Taiwan</em>: M.-T.M. Lee, Y.-T. Chen; Chang Gung Memorial Hospital, Chang Gung University, Taipei, Taiwan: M.-S. Wen; China Medical University, Graduate Institute of Chinese Medical Science, Taichung, Taiwan: M.-T.M. Lee; <em>Hadassah Medical Organization, Jerusalem, Israel</em>: Y. Caraco, I. Achache, S. Blotnick, M. Muszkat; <em>Inje University, Busan, Korea</em>: J.-G. Shin, H.-S. Kim; <em>Instituto Nacional de Câncer, Rio de Janeiro</em>: G. Suarez-Kurtz, J. Alessandra Perini; Instituto Nacional de Cardiologia Laranjeiras, Rio de Janeiro: E. Silva-Assunção; <em>Intermountain Healthcare, Salt Lake City</em>: J.L. Anderson, B.D. Horne, J.F. Carlquist; <em>Marshfield Clinic, Marshfield, WI</em>: M.D. Caldwell, R.L. Berg, J.K. Burmester; <em>National University Hospital, Singapore</em>: B.C. Goh, S.-C. Lee; <em>Newcastle University, Newcastle, United Kingdom</em>: F. Kamali, E. Sconce, A.K. Daly; <em>University of Alabama, Birmingham</em>: N.A. Limdi; <em>University of California, San Francisco</em>: A.H.B. Wu; <em>University of Florida, Gainesville</em>: J.A. Johnson, T.Y. Langaee, H. Feng; <em>University of Illinois, Chicago</em>: L. Cavallari, K. Momary; <em>University of Liverpool, Liverpool, United Kingdom</em>: M. Pirmohamed, A. Jorgensen, C.H. Toh, P. Williamson; <em>University of North Carolina, Chapel Hill</em>: H. McLeod, J.P. Evans, K.E. Weck; <em>University of Pennsylvania, Philadelphia</em>: S.E. Kimmel, C. Brensinger; University of Tokyo and RIKEN Center for Genomic Medicine, Tokyo: Y. Nakamura, T. Mushiroda; <em>University of Washington, Seattle</em>: D. Veenstra, L. Meckley, M.J. Rieder, A.E. Rettie; <em>Uppsala University, Uppsala, Sweden</em>: M. Wadelius, N. Eriksson, H. Melhus; <em>Vanderbilt University, Nashville</em>: C.M. Stein, D.M. Roden, U. Schwartz, D. Kurnik; <em>Washington University in St. Louis, St. Louis</em>: B.F. Gage, E. Deych, P. Lenzini, C. Eby; Wellcome Trust Sanger Institute, Hinxton, United Kingdom: L.Y. Chen, P. Deloukas; <strong>Statistical Analysis</strong> — <em>University of Alabama, Birmingham</em>: N.A. Limdi; <em>Marshfield Clinic, Marshfield, WI</em>: M.D. Caldwell; <em>North Carolina State University, Raleigh</em>: A. Motsinger-Reif; <em>Stanford University, Palo Alto, CA</em>: R.B. Altman, H. Sagreiya, T.E. Klein, B.S. Srinivasan; Uppsala University, Uppsala Clinical Research Center, Uppsala, Sweden: N. Eriksson; <em>University of California, San Francisco</em>: A.H.B. Wu; <em>University of North Carolina, Chapel Hill</em>: M.J. Wagner; <em>University of Florida, Gainesville</em>: J.A. Johnson; <em>University of Pennsylvania, Philadelphia</em>: S.E. Kimmel; <em>University of Wisconsin–Madison</em>: D. Page, E. Lantz, T. Chang; <em>Vanderbilt University, Nashville</em>: M. Ritchie; <em>Washington University in St. Louis, St. Louis</em>: B.F. Gage, E. Deych; <strong>Genotyping Quality Control of Consortium Samples</strong> — <em>Academic Sinica, Taipei, Taiwan</em>: M.-T.M. Lee, L.-S. Lu; <strong>Genotype and Phenotype Quality Control</strong> — <em>Inje University, Busan, Korea</em>: J.-G. Shin; <em>Marshfield Clinic, Marshfield, WI</em>: M.D. Caldwell; <em>Stanford University, Palo Alto, CA</em>: T.E. Klein, R.B. Altman, B.S. Srinivasan; <em>University of Alabama, Birmingham</em>: N.A. Limdi; <em>University of Florida, Gainesville</em>: J.A. Johnson; <em>University of Pennsylvania, Philadelphia</em>: S.E. Kimmel; <em>University of North Carolina, Chapel Hill</em>: M.J. Wagner; <em>University of Wisconsin–Madison</em>: D. Page; <em>Washington University in St. Louis, St. Louis</em>: B.F. Gage; <em>Vanderbilt University, Nashville</em>: M. Ritchie; <strong>Data Curation</strong> — <em>Stanford University, Palo Alto, CA</em>: T.E. Klein, R.B. Altman, B.S. Srinivasan; <em>University of North Carolina, Chapel Hill</em>: M.J. Wagner; <em>Washington University in St. Louis, St. Louis</em>: E. Deych.</p></div><div id="__ref-listid1192757" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-21"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-22">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__ref-listid1192757title">REFERENCES</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="R1">1. <span class="element-citation">Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. <span><span class="ref-journal">Arch Intern Med. </span>2007;<span class="ref-vol">167</span>:1414–9.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/17620536" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=nihms">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R2">2. <span class="element-citation">Budnitz DS, Shehab N, Kegler SR, Richards CL. Medication use leading to emergency department visits for adverse drug events in older adults. <span><span class="ref-journal">Ann Intern Med. </span>2007;<span class="ref-vol">147</span>:755–65.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/18056659" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=nihms">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R3">3. <span class="element-citation">Anderson JL, Horne BD, Stevens SM, et al.  Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. <span><span class="ref-journal">Circulation. </span>2007;<span class="ref-vol">116</span>:2563–70.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/17989110" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=nihms">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R4">4. <span class="element-citation">Aquilante CL, Langaee TY, Lopez LM, et al.  Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. <span><span class="ref-journal">Clin Pharmacol Ther. </span>2006;<span class="ref-vol">79</span>:291–302.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/16580898" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=nihms">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R5">5. <span class="element-citation">Caldwell MD, Awad T, Johnson JA, et al.  CYP4F2 genetic variant alters required warfarin dose. <span><span class="ref-journal">Blood. </span>2008;<span class="ref-vol">111</span>:4106–12.</span> <span class="nowrap ref pmc">[<a class="int-reflink" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2288721/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/18250228" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=nihms">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R6">6. <span class="element-citation">D'Andrea G, D'Ambrosio RL, Di Perna P, et al.  A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. <span><span class="ref-journal">Blood. </span>2005;<span class="ref-vol">105</span>:645–9.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15358623" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=nihms">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R7">7. <span class="element-citation">Herman D, Peternel P, Stegnar M, Breskvar K, Dolzan V. The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement. <span><span class="ref-journal">Thromb Haemost. </span>2006;<span class="ref-vol">95</span>:782–7.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/16676068" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=nihms">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R8">8. <span class="element-citation">Kimura R, Miyashita K, Kokubo Y, et al.  Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. <span><span class="ref-journal">Thromb Res. </span>2007;<span class="ref-vol">120</span>:181–6.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/17049586" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=nihms">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R9">9. <span class="element-citation">Millican EA, Lenzini PA, Milligan PE, et al.  Genetic-based dosing in orthopedic patients beginning warfarin therapy. <span><span class="ref-journal">Blood. </span>2007;<span class="ref-vol">110</span>:1511–5.</span> <span class="nowrap ref pmc">[<a class="int-reflink" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1975838/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/17387222" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=nihms">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R10">10. <span class="element-citation">Momary KM, Shapiro NL, Viana MA, Nutescu EA, Helgason CM, Cavallari LH. Factors influencing warfarin dose requirements in African-Americans. <span><span class="ref-journal">Pharmacogenomics. </span>2007;<span class="ref-vol">8</span>:1535–44.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/18034618" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=nihms">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R11">11. <span class="element-citation">Rieder MJ, Reiner AP, Gage BF, et al.  Effect of <em>VKORC1</em> haplotypes on transcriptional regulation and warfarin dose. <span><span class="ref-journal">N Engl J Med. </span>2005;<span class="ref-vol">352</span>:2285–93.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15930419" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=nihms">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R12">12. <span class="element-citation">Schelleman H, Chen Z, Kealey C, et al.  Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians. <span><span class="ref-journal">Clin Pharmacol Ther. </span>2007;<span class="ref-vol">81</span>:742–7.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/17329985" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=nihms">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R13">13. <span class="element-citation">Sconce EA, Khan TI, Wynne HA, et al.  The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. <span><span class="ref-journal">Blood. </span>2005;<span class="ref-vol">106</span>:2329–33.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15947090" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=nihms">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R14">14. <span class="element-citation">Takahashi H, Wilkinson GR, Nutescu EA, et al.  Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. <span><span class="ref-journal">Pharmacogenet Genomics. </span>2006;<span class="ref-vol">16</span>:101–10.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/16424822" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=nihms">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R15">15. <span class="element-citation">Tham LS, Goh BC, Nafziger A, et al.  A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. <span><span class="ref-journal">Clin Pharmacol Ther. </span>2006;<span class="ref-vol">80</span>:346–55.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/17015052" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=nihms">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R16">16. <span class="element-citation">Vecsler M, Loebstein R, Almog S, et al.  Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin. <span><span class="ref-journal">Thromb Haemost. </span>2006;<span class="ref-vol">95</span>:205–11.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/16493479" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=nihms">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R17">17. <span class="element-citation">Wadelius M, Chen LY, Downes K, et al.  Common VKORC1 and GGCX polymorphisms associated with warfarin dose. <span><span class="ref-journal">Pharmacogenomics J. </span>2005;<span class="ref-vol">5</span>:262–70.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15883587" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=nihms">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R18">18. <span class="element-citation">Wu AH. Use of genetic and nongenetic factors in warfarin dosing algorithms. <span><span class="ref-journal">Pharmacogenomics. </span>2007;<span class="ref-vol">8</span>:851–61.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/18240910" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=nihms">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R19">19. <span class="element-citation">Loebstein R, Dvoskin I, Halkin H, et al.  A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. <span><span class="ref-journal">Blood. </span>2007;<span class="ref-vol">109</span>:2477–80.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/17110455" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=nihms">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R20">20. <span class="element-citation">Caldwell MD, Berg RL, Zhang KQ, et al.  Evaluation of genetic factors for warfarin dose prediction. <span><span class="ref-journal">Clin Med Res. </span>2007;<span class="ref-vol">5</span>:8–16.</span> [Erratum, Clin Med Res 2007;5:142.] <span class="nowrap ref pmc">[<a class="int-reflink" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1855340/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/17456829" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=nihms">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R21">21. <span class="element-citation">Bussey HI, Wittkowsky AK, Hylek EM, Walker MB. Genetic testing for warfarin dosing? Not yet ready for prime time. <span><span class="ref-journal">Pharmacotherapy. </span>2008;<span class="ref-vol">28</span>:141–3.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/18225960" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=nihms">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R22">22. <span class="element-citation">Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. <span><span class="ref-journal">Clin Pharmacol Ther. </span>2008;<span class="ref-vol">83</span>:460–70.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/17851566" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=nihms">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R23">23. <span class="element-citation">Shurin SB, Nabel EG. Pharmacogenomics — ready for prime time? <span><span class="ref-journal">N Engl J Med. </span>2008;<span class="ref-vol">358</span>:1061–3.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/18322288" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=nihms">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R24">24. <span class="element-citation">Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. <span><span class="ref-journal">BMJ. </span>1995;<span class="ref-vol">310</span>:452–4.</span> [Erratum, BMJ 1995;310:1056.] <span class="nowrap ref pmc">[<a class="int-reflink" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2548824/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/7873954" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=nihms">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R25">25. <span class="element-citation">McWilliam A, Lutter A, Nardinelli C. Healthcare impact of personalized medicine using genetic testing: an exploratory analysis for warfarin. <span><span class="ref-journal">Personalized Med. </span>2008;<span class="ref-vol">5</span>:279–84.</span></span></div><div class="ref-cit-blk half_rhythm" id="R26">26. <span class="element-citation">Harrington DJ, Underwood S, Morse C, Shearer MJ, Tuddenham EG, Mumford AD. Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1. <span><span class="ref-journal">Thromb Haemost. </span>2005;<span class="ref-vol">93</span>:23–6.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15630486" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=nihms">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R27">27. <span class="element-citation">Rost S, Fregin A, Ivaskevicius V, et al.  Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. <span><span class="ref-journal">Nature. </span>2004;<span class="ref-vol">427</span>:537–41.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/14765194" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=nihms">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R28">28. <span class="element-citation">Scott SA, Edelmann L, Kornreich R, Desnick RJ. Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. <span><span class="ref-journal">Am J Hum Genet. </span>2008;<span class="ref-vol">82</span>:495–500.</span> <span class="nowrap ref pmc">[<a class="int-reflink" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427171/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/18252229" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=nihms">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R29">29. <span class="element-citation">Kimmel SE, Christie J, Kealey C, et al.  Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans. <span><span class="ref-journal">Pharmacogenomics J. </span>2008;<span class="ref-vol">8</span>:53–60.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/17325732" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=nihms">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R30">30. <span class="element-citation">Sconce EA, Daly AK, Khan TI, Wynne HA, Kamali F. APOE genotype makes a small contribution to warfarin dose requirements. <span><span class="ref-journal">Pharmacogenet Genomics. </span>2006;<span class="ref-vol">16</span>:609–11.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/16847429" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=nihms">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R31">31. <span class="element-citation">Wadelius M, Chen LY, Eriksson N, et al.  Association of warfarin dose with genes involved in its action and metabolism. <span><span class="ref-journal">Hum Genet. </span>2007;<span class="ref-vol">121</span>:23–34.</span> <span class="nowrap ref pmc">[<a class="int-reflink" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1797064/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/17048007" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=nihms">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R32">32. <span class="element-citation">Holbrook AM, Pereira JA, Labiris R, et al.  Systematic overview of warfarin and its drug and food interactions. <span><span class="ref-journal">Arch Intern Med. </span>2005;<span class="ref-vol">165</span>:1095–106.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15911722" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=nihms">PubMed</a>]</span></span></div></div></div><div style="display: none; width: 200px; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbilinksmenu"><ul id="ui-ncbiinpagenav-2"><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#__abstractid648639title">Abstract</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#S5title">METHODS</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#S9title">RESULTS</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#S14title">DISCUSSION</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#SMtitle">Supplementary Material</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#S15title">Acknowledgments</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#APP1title">APPENDIX</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#__ref-listid1192757title">REFERENCES</a></li></ul></div></div><!--post-content--></div>
            
            
        
            
        </div>
        <!-- Book content -->
    </div>
    
    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            
        </div>
        
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><div class="try-button"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/?report=reader"><img src="./PMC2722908_files/3838809" alt="PubReader format: click here to try"></a></div><div class="format-menu"><h2>Formats:</h2><ul><li class="selected">Article</li> | <li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/?report=reader">PubReader</a></li> | <li class="epub-link"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/epub/">ePub (beta)</a></li> | <li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/pdf/ukmss-5142.pdf">PDF (574K)</a></li> | <li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#" data-citationid="PMC2722908" class="citationexporter ctxp" role="button" aria-expanded="false" aria-haspopup="true">Citation</a></li></ul></div></div><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="share-buttons"><h2>Share</h2><ul><li class="facebook"><a href="https://www.facebook.com/sharer/sharer.php?u=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2722908%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="./PMC2722908_files/4047626" alt="Share on Facebook">
                             Facebook
                        </a></li><li class="twitter"><a href="https://twitter.com/intent/tweet?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2722908%2F&amp;text=Estimation%20of%20the%20Warfarin%20Dose%20with%20Clinical%20and%20Pharmacogenetic%20Data" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="./PMC2722908_files/4047627" alt="Share on Twitter">
                             Twitter
                        </a></li><li class="gplus"><a href="https://plus.google.com/share?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2722908%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="./PMC2722908_files/4047628" alt="Share on Google Plus">
                             Google+
                        </a></li></ul></div>
        
        <div id="ajax-portlets" data-pmid="19228618" data-aiid="2722908" data-aid="2722908" data-iid="179570" data-domainid="358" data-domain="wtpa" data-accid="PMC2722908" data-md5="6225ab6023afd6838cc6a0f91ea63d5c">
<div class="portlet pubmed_favoritesad">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Save items</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="pmfavad" toggles="ui-portlet_content-25" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-25" aria-hidden="false"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<input type="hidden" name="absid" id="absid" value="2722908"><div id="pubmed_favoritesad" class="empty" data-db="pmc">
<span role="menubar"><div class="ui-ncbisetswitch ltd-hover" role="menuitem" aria-expanded="false" aria-haspopup="true"><a href="http://www.ncbi.nlm.nih.gov/myncbi/collections/" class="jig-ncbisetswitch blind collink ltd-hover ui-ncbisetswitch-hasStar" id="favList" data-jigconfig="destSelector:&#39;#favUL&#39;,starExists:true,createCollectionUrl:&#39;#&#39;,manageCollectionsUrl:&#39;/myncbi/collections/&#39;"><span class="star"></span>Add to Favorites</a><a class="ui-ncbisetswitch-button ltd-hover" title="View more options" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#"><span class="ui-icon ui-icon-triangle-1-s ui-ncbisetswitch-down">View more options</span></a></div></span><div style="display: none; width: 200px; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbilinksmenu ui-ncbisetswitch-popper"><ul id="favUL" class="ui-ncbisetswitch-options"></ul><ul class="ui-ncbisetswitch-actions"><li class="ui-ncbisetswitch-actions-create" style="display: block;"><a class="ui-ncbisetswitch-create-collection" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#">Create collection...</a></li><li class="ui-ncbisetswitch-actions-manage" style="display: block;"><a class="ui-ncbisetswitch-manage-collections" href="http://www.ncbi.nlm.nih.gov/myncbi/collections/">Manage collections...</a></li></ul></div>
</div>
<div class="colloading">loading</div>
<span id="submenu_AddToCollections"><form method="post"><input type="submit" class="button_apply" name="addtocollection" value="1"></form></span>
</div></div></div>
</div><div class="portlet">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" toggles="ui-portlet_content-27" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-27" aria-hidden="false">
<ul>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/23839801" ref="reftype=relart&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients.</a><span class="source">[Mol Diagn Ther. 2013]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-29" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Ekladious SM, Issac MS, El-Atty Sharaf SA, Abou-Youssef HS. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Mol Diagn Ther. 2013 Dec; 17(6):381-90. </em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/22851439" ref="reftype=relart&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Validation of pharmacogenetic algorithms and warfarin dosing table in Egyptian patients.</a><span class="source">[Int J Clin Pharm. 2012]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-31" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Bazan NS, Sabry NA, Rizk A, Mokhtar S, Badary O. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Int J Clin Pharm. 2012 Dec; 34(6):837-44. Epub 2012 Jul 27.</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/21450231" ref="reftype=relart&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Failure of pharmacogenetic-based dosing algorithms to identify older patients requiring low daily doses of warfarin.</a><span class="source">[J Am Med Dir Assoc. 2011]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-33" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Schwartz JB, Kane L, Moore K, Wu AH. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Am Med Dir Assoc. 2011 Nov; 12(9):633-8. Epub 2011 Jan 26.</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/21900891" ref="reftype=relart&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.</a><span class="source">[Clin Pharmacol Ther. 2011]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-35" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein CM, Anderson JL, Kimmel SE, Lee MT, Pirmohamed M, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Clin Pharmacol Ther. 2011 Oct; 90(4):625-9. Epub 2011 Sep 7.</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/23047421" ref="reftype=relart&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Warfarin pharmacogenetics: does more accurate dosing benefit patients?</a><span class="source">[Semin Thromb Hemost. 2012]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-37" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Eby C. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Semin Thromb Hemost. 2012 Oct; 38(7):661-6. Epub 2012 Oct 9.</em>
</div>
</li>
</ul>
<a class="seemore" href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=19228618&amp;log%24=relatedreviews&amp;logdbfrom=pmc" ref="reftype=relart&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Reviews&amp;rendering-type=normal">See reviews...</a><a class="seemore" href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=19228618&amp;log%24=relatedarticles&amp;logdbfrom=pmc" ref="reftype=relart&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Related%20Records&amp;rendering-type=normal">See all...</a>
</div></div>
</div><div class="portlet">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Cited by other articles in PMC</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="PMCVCitedByPmcArticlesP" toggles="ui-portlet_content-39" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-39" aria-hidden="false">
<ul>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4899997/" ref="reftype=relart&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Verification of five pharmacogenomics-based warfarin administration models</a><span class="source">[Indian Journal of Pharmacology...]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-41" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lin M, Yu L, Qiu H, Wang Q, Zhang J, Song H. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Indian Journal of Pharmacology. 2016 May-Jun; 48(3)258-263</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4852013/" ref="reftype=relart&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Influence of the CYP4F2 polymorphism on the risk of hemorrhagic complications in coumarin-treated patients</a><span class="source">[Saudi Medical Journal. 2016]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-43" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Chen P, Sun YQ, Yang GP, Li R, Pan J, Zhou YS. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Saudi Medical Journal. 2016 Apr; 37(4)361-368</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4849475/" ref="reftype=relart&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Cardiovascular pharmacogenomics: current status and future directions</a><span class="source">[Journal of human genetics. 2015]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-45" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Roden DM. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Journal of human genetics. 2015 Jul 16; 61(1)79-85</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845354/" ref="reftype=relart&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Individualized versus standardized risk assessment in patients at high risk for adverse drug reactions (IDrug) – study protocol for a pragmatic randomized controlled trial</a><span class="source">[BMC Family Practice. 2016]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-47" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Stingl JC, Kaumanns KL, Claus K, Lehmann ML, Kastenmüller K, Bleckwenn M, Hartmann G, Steffens M, Wirtz D, Leuchs AK, Benda N, Meier F, Schöffski O, Holdenrieder S, Coch C, Weckbecker K. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">BMC Family Practice. 2016 Apr 26; 1749</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827719/" ref="reftype=relart&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Privacy in Pharmacogenetics: An End-to-End Case Study of Personalized Warfarin Dosing</a><span class="source">[Proceedings of the ... USENIX ...]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-49" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Fredrikson M, Lantz E, Jha S, Lin S, Page D, Ristenpart T. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Proceedings of the ... USENIX Security Symposium. UNIX Security Symposium. 2014 Aug; 201417-32</em>
</div>
</li>
</ul>
<a class="seemore" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/citedby/" ref="reftype=relart&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|CitedBy&amp;rendering-type=normal">See all...</a>
</div></div>
</div><div class="portlet">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Links</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="PMCVCitedByPmcArticlesP" toggles="ui-portlet_content-51" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-51" aria-hidden="false"><ul>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/?Db=books&amp;DbFrom=pmc&amp;Cmd=Link&amp;LinkName=pmc_books_refs&amp;IdsFromResult=2722908" ref="reftype=Cited%20in%20Books&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|Crosslink|Books&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Cited in Books</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-53" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">Cited in Books<div class="brieflinkpopdesc">PubMed Central articles cited in books</div>
</div>
</li>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/?Db=clinvar&amp;DbFrom=pmc&amp;Cmd=Link&amp;LinkName=pmc_clinvar&amp;IdsFromResult=2722908" ref="reftype=ClinVar&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|Crosslink|Unknown%20Link%20Name&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">ClinVar</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-55" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">ClinVar<div class="brieflinkpopdesc">Links to ClinVar</div>
</div>
</li>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/?Db=pccompound&amp;DbFrom=pmc&amp;Cmd=Link&amp;LinkName=pmc_pccompound&amp;IdsFromResult=2722908" ref="reftype=Compound&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|Crosslink|PubChem%20Compound&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Compound</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-57" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">Compound<div class="brieflinkpopdesc">PubChem Compound links</div>
</div>
</li>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/?Db=medgen&amp;DbFrom=pmc&amp;Cmd=Link&amp;LinkName=pmc_medgen&amp;IdsFromResult=2722908" ref="reftype=MedGen&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|Crosslink|Unknown%20Link%20Name&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">MedGen</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-59" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">MedGen<div class="brieflinkpopdesc">Related information in MedGen</div>
</div>
</li>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/19228618/" ref="reftype=PubMed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|PubMed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">PubMed</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-61" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">PubMed<div class="brieflinkpopdesc">PubMed citations for these articles</div>
</div>
</li>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/?Db=snp&amp;DbFrom=pmc&amp;Cmd=Link&amp;LinkName=pmc_snp&amp;IdsFromResult=2722908" ref="reftype=SNP&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|Crosslink|SNP&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">SNP</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-63" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">SNP<div class="brieflinkpopdesc">PMC to SNP links</div>
</div>
</li>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/?Db=pcsubstance&amp;DbFrom=pmc&amp;Cmd=Link&amp;LinkName=pmc_pcsubstance&amp;IdsFromResult=2722908" ref="reftype=Substance&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|Crosslink|PubChem%20Substance&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Substance</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-65" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">Substance<div class="brieflinkpopdesc">PubChem Substance links</div>
</div>
</li>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/?Db=taxonomy&amp;DbFrom=pmc&amp;Cmd=Link&amp;LinkName=pmc_taxonomy&amp;IdsFromResult=2722908" ref="reftype=Taxonomy&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|Crosslink|Taxonomy&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Taxonomy</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-67" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">Taxonomy<div class="brieflinkpopdesc">Related taxonomy entry</div>
</div>
</li>
</ul></div></div>
</div><div class="portlet">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Recent Activity</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" toggles="ui-portlet_content-69" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-69" aria-hidden="false"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class="">
<div class="action">
<a href="javascript:historyDisplayState(&#39;ClearHT&#39;)">Clear</a><a href="javascript:historyDisplayState(&#39;HTOff&#39;)" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState(&#39;HTOn&#39;)" class="HTOff">Turn On</a>
</div>
<ul id="activity">
<li class="ra_rcd ralinkpopper two_line">
<a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c27da04fcfad59176bb02">Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data</a><div class="ralinkpop offscreen_noflow">Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data<div class="brieflinkpopdesc">UKPMC Funders Author Manuscripts. 2009 Feb 19; 360(8)753</div>
</div>
<div class="tertiary"></div>
</li>
<li class="ra_qry two_line">
<a class="htb" ref="log$=activity&amp;linkpos=2" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c27d704fcfad59176ba76">PMC2722908 <span class="number">(1)</span></a><div class="tertiary">PMC</div>
</li>
<li class="ra_rcd ralinkpopper two_line">
<a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=3" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c27bc04fcfad59176b5fc">The pharmacokinetics and pharmacodynamics of warfarin in combination with ambris...</a><div class="ralinkpop offscreen_noflow">The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers<div class="brieflinkpopdesc">British Journal of Clinical Pharmacology. 2009 May; 67(5)527</div>
</div>
<div class="tertiary"></div>
</li>
<li class="ra_qry two_line">
<a class="htb" ref="log$=activity&amp;linkpos=4" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c27b9f2911de5257d8dc4">PMC2686069 <span class="number">(1)</span></a><div class="tertiary">PMC</div>
</li>
<li class="ra_rcd ralinkpopper two_line">
<a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=5" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c277b04fcfad59176aad9">Assessment of a pharmacokinetic and pharmacodynamic interaction between simvasta...</a><div class="ralinkpop offscreen_noflow">Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects<div class="brieflinkpopdesc">British Journal of Clinical Pharmacology. 2009 May; 67(5)520</div>
</div>
<div class="tertiary"></div>
</li>
</ul>
<p class="HTOn">Your browsing activity is empty.</p>
<p class="HTOff">Activity recording is turned off.</p>
<p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState(&#39;HTOn&#39;)">Turn recording back on</a></p>
<a class="seemore" href="http://www.ncbi.nlm.nih.gov/sites/myncbi/recentactivity">See more...</a>
</div></div></div>
</div>
<div>
<div class="portlet brieflink pmc_para_cit" id="crb--P5" name="crb--P5" rid="P5" style="position: absolute; visibility: visible; width: 370px; top: 1140px; display: none;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-71"><ul>
<li class="two_line" reference_id="R1">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/17620536/" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action.</a><span class="one_line_source">[Arch Intern Med.  2007]</span><div class="alt-note">
<div class="authors">Wysowski DK, Nourjah P, Swartz L</div>
<div class="citation">Arch Intern Med. 2007 Jul 9; 167(13):1414-9.</div>
</div>
</li>
<li class="two_line" reference_id="R2">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/18056659/" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Medication use leading to emergency department visits for adverse drug events in older adults.</a><span class="one_line_source">[Ann Intern Med.  2007]</span><div class="alt-note">
<div class="authors">Budnitz DS, Shehab N, Kegler SR, Richards CL</div>
<div class="citation">Ann Intern Med. 2007 Dec 4; 147(11):755-65.</div>
</div>
</li>
</ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--P6" name="crb--P6" rid="P6" style="position: absolute; visibility: visible; width: 370px; top: 1260px; display: none;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-72"><ul>
<li class="two_line" reference_id="R3">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/17989110/" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation.</a><span class="one_line_source">[Circulation.  2007]</span><div class="alt-note">
<div class="authors">Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP, Kahn SF, May HT, Samuelson KM, Muhlestein JB, Carlquist JF, Couma-Gen Investigators</div>
<div class="citation">Circulation. 2007 Nov 27; 116(22):2563-70.</div>
</div>
</li>
<li class="two_line" reference_id="R18">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/18240910/" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal"><span class="invert">Review</span> Use of genetic and nongenetic factors in warfarin dosing algorithms.</a><span class="one_line_source">[Pharmacogenomics.  2007]</span><div class="alt-note">
<div class="authors">Wu AH</div>
<div class="citation">Pharmacogenomics. 2007 Jul; 8(7):851-61.</div>
</div>
</li>
<li class="two_line" reference_id="R19">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/17110455/" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance.</a><span class="one_line_source">[Blood.  2007]</span><div class="alt-note">
<div class="authors">Loebstein R, Dvoskin I, Halkin H, Vecsler M, Lubetsky A, Rechavi G, Amariglio N, Cohen Y, Ken-Dror G, Almog S, Gak E</div>
<div class="citation">Blood. 2007 Mar 15; 109(6):2477-80.</div>
</div>
</li>
<li class="two_line" reference_id="R5">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/18250228/" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">CYP4F2 genetic variant alters required warfarin dose.</a><span class="one_line_source">[Blood.  2008]</span><div class="alt-note">
<div class="authors">Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P, Hubbard J, Turpaz Y, Langaee TY, Eby C, King CR, Brower A, Schmelzer JR, Glurich I, Vidaillet HJ, Yale SH, Qi Zhang K, Berg RL, Burmester JK</div>
<div class="citation">Blood. 2008 Apr 15; 111(8):4106-12.</div>
</div>
</li>
<li class="two_line" reference_id="R9">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/17387222/" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Genetic-based dosing in orthopedic patients beginning warfarin therapy.</a><span class="one_line_source">[Blood.  2007]</span><div class="alt-note">
<div class="authors">Millican EA, Lenzini PA, Milligan PE, Grosso L, Eby C, Deych E, Grice G, Clohisy JC, Barrack RL, Burnett RS, Voora D, Gatchel S, Tiemeier A, Gage BF</div>
<div class="citation">Blood. 2007 Sep 1; 110(5):1511-5.</div>
</div>
</li>
<li class="two_line" reference_id="R13">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/15947090/" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.</a><span class="one_line_source">[Blood.  2005]</span><div class="alt-note">
<div class="authors">Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F</div>
<div class="citation">Blood. 2005 Oct 1; 106(7):2329-33.</div>
</div>
</li>
<li class="two_line" reference_id="R20">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/17456829/" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Evaluation of genetic factors for warfarin dose prediction.</a><span class="one_line_source">[Clin Med Res.  2007]</span><div class="alt-note">
<div class="authors">Caldwell MD, Berg RL, Zhang KQ, Glurich I, Schmelzer JR, Yale SH, Vidaillet HJ, Burmester JK</div>
<div class="citation">Clin Med Res. 2007 Mar; 5(1):8-16.</div>
</div>
</li>
<li class="two_line" reference_id="R21" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/18225960/" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Genetic testing for warfarin dosing? Not yet ready for prime time.</a><span class="one_line_source">[Pharmacotherapy.  2008]</span><div class="alt-note">
<div class="authors">Bussey HI, Wittkowsky AK, Hylek EM, Walker MB</div>
<div class="citation">Pharmacotherapy. 2008 Feb; 28(2):141-3.</div>
</div>
</li>
<li class="two_line" reference_id="R22" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/17851566/" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.</a><span class="one_line_source">[Clin Pharmacol Ther.  2008]</span><div class="alt-note">
<div class="authors">Caraco Y, Blotnick S, Muszkat M</div>
<div class="citation">Clin Pharmacol Ther. 2008 Mar; 83(3):460-70.</div>
</div>
</li>
<li class="two_line" reference_id="R23" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/18322288/" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Pharmacogenomics--ready for prime time?</a><span class="one_line_source">[N Engl J Med.  2008]</span><div class="alt-note">
<div class="authors">Shurin SB, Nabel EG</div>
<div class="citation">N Engl J Med. 2008 Mar 6; 358(10):1061-3.</div>
</div>
</li>
</ul><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/" class="seemore">See more ...</a></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--P8" name="crb--P8" rid="P8" style="position: absolute; visibility: visible; width: 370px; top: 1854px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-73"><ul><li class="two_line" reference_id="R11">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/15930419/" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.</a><span class="one_line_source">[N Engl J Med.  2005]</span><div class="alt-note">
<div class="authors">Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE</div>
<div class="citation">N Engl J Med. 2005 Jun 2; 352(22):2285-93.</div>
</div>
</li></ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--P13" name="crb--P13" rid="P13" style="position: absolute; visibility: visible; width: 370px; top: 3158px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-74"><ul><li class="two_line" reference_id="R24">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/7873954/" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">The number needed to treat: a clinically useful measure of treatment effect.</a><span class="one_line_source">[BMJ.  1995]</span><div class="alt-note">
<div class="authors">Cook RJ, Sackett DL</div>
<div class="citation">BMJ. 1995 Feb 18; 310(6977):452-4.</div>
</div>
</li></ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--P22" name="crb--P22" rid="P22" style="position: absolute; visibility: visible; width: 370px; top: 6589px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-75"><ul>
<li class="two_line" reference_id="R19">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/17110455/" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance.</a><span class="one_line_source">[Blood.  2007]</span><div class="alt-note">
<div class="authors">Loebstein R, Dvoskin I, Halkin H, Vecsler M, Lubetsky A, Rechavi G, Amariglio N, Cohen Y, Ken-Dror G, Almog S, Gak E</div>
<div class="citation">Blood. 2007 Mar 15; 109(6):2477-80.</div>
</div>
</li>
<li class="two_line" reference_id="R28">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/18252229/" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations.</a><span class="one_line_source">[Am J Hum Genet.  2008]</span><div class="alt-note">
<div class="authors">Scott SA, Edelmann L, Kornreich R, Desnick RJ</div>
<div class="citation">Am J Hum Genet. 2008 Feb; 82(2):495-500.</div>
</div>
</li>
</ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--P23" name="crb--P23" rid="P23" style="position: absolute; visibility: visible; width: 370px; top: 6770px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-76"><ul>
<li class="two_line" reference_id="R4">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/16580898/" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.</a><span class="one_line_source">[Clin Pharmacol Ther.  2006]</span><div class="alt-note">
<div class="authors">Aquilante CL, Langaee TY, Lopez LM, Yarandi HN, Tromberg JS, Mohuczy D, Gaston KL, Waddell CD, Chirico MJ, Johnson JA</div>
<div class="citation">Clin Pharmacol Ther. 2006 Apr; 79(4):291-302.</div>
</div>
</li>
<li class="two_line" reference_id="R5">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/18250228/" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">CYP4F2 genetic variant alters required warfarin dose.</a><span class="one_line_source">[Blood.  2008]</span><div class="alt-note">
<div class="authors">Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P, Hubbard J, Turpaz Y, Langaee TY, Eby C, King CR, Brower A, Schmelzer JR, Glurich I, Vidaillet HJ, Yale SH, Qi Zhang K, Berg RL, Burmester JK</div>
<div class="citation">Blood. 2008 Apr 15; 111(8):4106-12.</div>
</div>
</li>
<li class="two_line" reference_id="R16">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/16493479/" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin.</a><span class="one_line_source">[Thromb Haemost.  2006]</span><div class="alt-note">
<div class="authors">Vecsler M, Loebstein R, Almog S, Kurnik D, Goldman B, Halkin H, Gak E</div>
<div class="citation">Thromb Haemost. 2006 Feb; 95(2):205-11.</div>
</div>
</li>
<li class="two_line" reference_id="R17">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/15883587/" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Common VKORC1 and GGCX polymorphisms associated with warfarin dose.</a><span class="one_line_source">[Pharmacogenomics J.  2005]</span><div class="alt-note">
<div class="authors">Wadelius M, Chen LY, Downes K, Ghori J, Hunt S, Eriksson N, Wallerman O, Melhus H, Wadelius C, Bentley D, Deloukas P</div>
<div class="citation">Pharmacogenomics J. 2005; 5(4):262-70.</div>
</div>
</li>
<li class="two_line" reference_id="R29">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/17325732/" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans.</a><span class="one_line_source">[Pharmacogenomics J.  2008]</span><div class="alt-note">
<div class="authors">Kimmel SE, Christie J, Kealey C, Chen Z, Price M, Thorn CF, Brensinger CM, Newcomb CW, Whitehead AS</div>
<div class="citation">Pharmacogenomics J. 2008 Feb; 8(1):53-60.</div>
</div>
</li>
<li class="two_line" reference_id="R31">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/17048007/" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Association of warfarin dose with genes involved in its action and metabolism.</a><span class="one_line_source">[Hum Genet.  2007]</span><div class="alt-note">
<div class="authors">Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, Wadelius C, Bentley D, McGinnis R, Deloukas P</div>
<div class="citation">Hum Genet. 2007 Mar; 121(1):23-34.</div>
</div>
</li>
<li class="two_line" reference_id="R32">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/15911722/" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal"><span class="invert">Review</span> Systematic overview of warfarin and its drug and food interactions.</a><span class="one_line_source">[Arch Intern Med.  2005]</span><div class="alt-note">
<div class="authors">Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS</div>
<div class="citation">Arch Intern Med. 2005 May 23; 165(10):1095-106.</div>
</div>
</li>
<li class="two_line" reference_id="R11">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/15930419/" ref="reftype=pubmed&amp;article-id=2722908&amp;issue-id=179570&amp;journal-id=358&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.</a><span class="one_line_source">[N Engl J Med.  2005]</span><div class="alt-note">
<div class="authors">Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE</div>
<div class="citation">N Engl J Med. 2005 Jun 2; 352(22):2285-93.</div>
</div>
</li>
</ul></div>
</div>
</div>   
    </div>
                
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script src="./PMC2722908_files/jquery.scrollTo-1.4.2.js"></script>
<script>
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>



<div id="body-link-poppers"><div id="body-link-popper-R1" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action.<div class="authors">Wysowski DK, Nourjah P, Swartz L</div><div class="citation">Arch Intern Med. 2007 Jul 9; 167(13):1414-9.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/17620536/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R1">Ref list</a>]</p></div><div id="body-link-popper-R2" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Medication use leading to emergency department visits for adverse drug events in older adults.<div class="authors">Budnitz DS, Shehab N, Kegler SR, Richards CL</div><div class="citation">Ann Intern Med. 2007 Dec 4; 147(11):755-65.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/18056659/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R2">Ref list</a>]</p></div><div id="body-link-popper-R3" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation.<div class="authors">Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP, Kahn SF, May HT, Samuelson KM, Muhlestein JB, Carlquist JF, Couma-Gen Investigators</div><div class="citation">Circulation. 2007 Nov 27; 116(22):2563-70.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/17989110/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R3">Ref list</a>]</p></div><div id="body-link-popper-R18" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="invert">Review</span> Use of genetic and nongenetic factors in warfarin dosing algorithms.<div class="authors">Wu AH</div><div class="citation">Pharmacogenomics. 2007 Jul; 8(7):851-61.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/18240910/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R18">Ref list</a>]</p></div><div id="body-link-popper-R19" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance.<div class="authors">Loebstein R, Dvoskin I, Halkin H, Vecsler M, Lubetsky A, Rechavi G, Amariglio N, Cohen Y, Ken-Dror G, Almog S, Gak E</div><div class="citation">Blood. 2007 Mar 15; 109(6):2477-80.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/17110455/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R19">Ref list</a>]</p></div><div id="body-link-popper-R5" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">CYP4F2 genetic variant alters required warfarin dose.<div class="authors">Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P, Hubbard J, Turpaz Y, Langaee TY, Eby C, King CR, Brower A, Schmelzer JR, Glurich I, Vidaillet HJ, Yale SH, Qi Zhang K, Berg RL, Burmester JK</div><div class="citation">Blood. 2008 Apr 15; 111(8):4106-12.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/18250228/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R5">Ref list</a>]</p></div><div id="body-link-popper-R9" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Genetic-based dosing in orthopedic patients beginning warfarin therapy.<div class="authors">Millican EA, Lenzini PA, Milligan PE, Grosso L, Eby C, Deych E, Grice G, Clohisy JC, Barrack RL, Burnett RS, Voora D, Gatchel S, Tiemeier A, Gage BF</div><div class="citation">Blood. 2007 Sep 1; 110(5):1511-5.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/17387222/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R9">Ref list</a>]</p></div><div id="body-link-popper-R13" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.<div class="authors">Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F</div><div class="citation">Blood. 2005 Oct 1; 106(7):2329-33.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15947090/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R13">Ref list</a>]</p></div><div id="body-link-popper-R20" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Evaluation of genetic factors for warfarin dose prediction.<div class="authors">Caldwell MD, Berg RL, Zhang KQ, Glurich I, Schmelzer JR, Yale SH, Vidaillet HJ, Burmester JK</div><div class="citation">Clin Med Res. 2007 Mar; 5(1):8-16.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/17456829/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R20">Ref list</a>]</p></div><div id="body-link-popper-R21" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Genetic testing for warfarin dosing? Not yet ready for prime time.<div class="authors">Bussey HI, Wittkowsky AK, Hylek EM, Walker MB</div><div class="citation">Pharmacotherapy. 2008 Feb; 28(2):141-3.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/18225960/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R21">Ref list</a>]</p></div><div id="body-link-popper-R22" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.<div class="authors">Caraco Y, Blotnick S, Muszkat M</div><div class="citation">Clin Pharmacol Ther. 2008 Mar; 83(3):460-70.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/17851566/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R22">Ref list</a>]</p></div><div id="body-link-popper-R23" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Pharmacogenomics--ready for prime time?<div class="authors">Shurin SB, Nabel EG</div><div class="citation">N Engl J Med. 2008 Mar 6; 358(10):1061-3.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/18322288/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R23">Ref list</a>]</p></div><div id="body-link-popper-R11" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.<div class="authors">Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE</div><div class="citation">N Engl J Med. 2005 Jun 2; 352(22):2285-93.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15930419/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R11">Ref list</a>]</p></div><div id="body-link-popper-R24" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">The number needed to treat: a clinically useful measure of treatment effect.<div class="authors">Cook RJ, Sackett DL</div><div class="citation">BMJ. 1995 Feb 18; 310(6977):452-4.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/7873954/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R24">Ref list</a>]</p></div><div id="body-link-popper-R25" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">25. <span class="element-citation">McWilliam A, Lutter A, Nardinelli C. Healthcare impact of personalized medicine using genetic testing: an exploratory analysis for warfarin. <span><span class="ref-journal">Personalized Med. </span>2008;<span class="ref-vol">5</span>:279–84.</span></span> [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R25">Ref list</a>]</div><div id="body-link-popper-R28" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations.<div class="authors">Scott SA, Edelmann L, Kornreich R, Desnick RJ</div><div class="citation">Am J Hum Genet. 2008 Feb; 82(2):495-500.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/18252229/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R28">Ref list</a>]</p></div><div id="body-link-popper-R4" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.<div class="authors">Aquilante CL, Langaee TY, Lopez LM, Yarandi HN, Tromberg JS, Mohuczy D, Gaston KL, Waddell CD, Chirico MJ, Johnson JA</div><div class="citation">Clin Pharmacol Ther. 2006 Apr; 79(4):291-302.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/16580898/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R4">Ref list</a>]</p></div><div id="body-link-popper-R16" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin.<div class="authors">Vecsler M, Loebstein R, Almog S, Kurnik D, Goldman B, Halkin H, Gak E</div><div class="citation">Thromb Haemost. 2006 Feb; 95(2):205-11.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/16493479/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R16">Ref list</a>]</p></div><div id="body-link-popper-R17" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Common VKORC1 and GGCX polymorphisms associated with warfarin dose.<div class="authors">Wadelius M, Chen LY, Downes K, Ghori J, Hunt S, Eriksson N, Wallerman O, Melhus H, Wadelius C, Bentley D, Deloukas P</div><div class="citation">Pharmacogenomics J. 2005; 5(4):262-70.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15883587/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R17">Ref list</a>]</p></div><div id="body-link-popper-R29" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans.<div class="authors">Kimmel SE, Christie J, Kealey C, Chen Z, Price M, Thorn CF, Brensinger CM, Newcomb CW, Whitehead AS</div><div class="citation">Pharmacogenomics J. 2008 Feb; 8(1):53-60.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/17325732/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R29">Ref list</a>]</p></div><div id="body-link-popper-R31" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Association of warfarin dose with genes involved in its action and metabolism.<div class="authors">Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, Wadelius C, Bentley D, McGinnis R, Deloukas P</div><div class="citation">Hum Genet. 2007 Mar; 121(1):23-34.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/17048007/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R31">Ref list</a>]</p></div><div id="body-link-popper-R32" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="invert">Review</span> Systematic overview of warfarin and its drug and food interactions.<div class="authors">Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS</div><div class="citation">Arch Intern Med. 2005 May 23; 165(10):1095-106.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15911722/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#R32">Ref list</a>]</p></div></div>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <div class="breadcrumbs">You are here: 
            <span id="breadcrumb_text"><a href="http://www.ncbi.nlm.nih.gov/guide/">NCBI</a> &gt; <a href="http://www.ncbi.nlm.nih.gov/guide/literature/">Literature</a> &gt; <a href="http://www.ncbi.nlm.nih.gov/pmc/">PubMed Central (PMC)</a></span></div>
    <a id="help-desk-link" class="help_desk jig-ncbihelpwindow" target="_blank" href="http://www.ncbi.nlm.nih.gov/sites/ehelp?&amp;Ncbi_App=pmc&amp;Db=pmc&amp;Page=literature&amp;Snapshot=/projects/PMC/PMCViewer@4.35&amp;Time=2016-06-23T14:18:02-04:00&amp;Host=ptpmc101">Write to the Help Desk</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="./PMC2722908_files/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="http://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="http://www.nlm.nih.gov/" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="http://www.nih.gov/" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="http://www.dhhs.gov/" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="http://www.usa.gov/" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            
            <a href="http://www.ncbi.nlm.nih.gov/About/disclaimer.html">Copyright</a> | <a href="http://www.ncbi.nlm.nih.gov/About/disclaimer.html#disclaimer">Disclaimer</a> |
            <a href="http://www.nlm.nih.gov/privacy.html" class="newdomain">Privacy</a> | 
            <a href="http://www.ncbi.nlm.nih.gov/guide/browsers/">Browsers</a> | <a href="http://www.nlm.nih.gov/accessibility.html">Accessibility</a> | <a href="http://www.ncbi.nlm.nih.gov/About/glance/contact_info.html">Contact</a>
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="http://www.ncbi.nlm.nih.gov/">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url"><a href="http://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
        </div>
    </div>
    <script type="text/javascript" src="./PMC2722908_files/InstrumentPageStarterJS.js"> </script>    
    <script type="text/javascript" src="./PMC2722908_files/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        <div style="display: none; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic">External link. Please review our <a href="http://www.nlm.nih.gov/privacy.html">privacy policy</a>.</div><div class="ui-ncbiautocomplete-holder shadow ui-ncbiautocomplete-holder-clearfix" aria-live="assertive" style="display: none; top: 63.5938px; left: 408.188px; width: 670px; z-index: 1001;"><ul class="ui-ncbiautocomplete-options" role="listbox" aria-activedescendant="term"></ul><div class="ui-ncbiautocomplete-actions shadow" style="display: none;"><a class="ui-ncbiautocomplete-link-pref" style="display: none;">Preferences</a><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722908/#" class="ui-ncbiautocomplete-link-off ui-ncbiautocomplete-link-pref-right" style="display: none;">Turn off</a></div></div></div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript>&lt;img alt="statistics" src="/stat?jsdisabled=true&amp;amp;ncbi_db=pmc&amp;amp;ncbi_pdid=article&amp;amp;ncbi_acc=&amp;amp;ncbi_domain=wtpa&amp;amp;ncbi_report=record&amp;amp;ncbi_type=fulltext&amp;amp;ncbi_objectid=&amp;amp;ncbi_pcid=/articles/PMC2722908/&amp;amp;ncbi_app=pmc" /&gt;</noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- F4FC7E8376854741_0014SID /projects/PMC/PMCViewer@4.35 ptpmc101 v4.1.r480124 Mon, Sep 28 2015 02:46:19 -->

<script type="text/javascript" src="./PMC2722908_files/4065628.js" snapshot="pmc"></script>
<div class="ui-dialog ui-widget ui-widget-content ui-corner-all ui-front" tabindex="-1" role="dialog" aria-describedby="epubDialog" aria-labelledby="ui-id-1" style="display: none;"><div class="ui-dialog-titlebar ui-widget-header ui-corner-all ui-helper-clearfix"><span id="ui-id-1" class="ui-dialog-title">Making articles easier to read in PMC</span><button type="button" class="ui-button ui-widget ui-state-default ui-corner-all ui-button-icon-only ui-dialog-titlebar-close" role="button" title="Close"><span class="ui-button-icon-primary ui-icon ui-icon-closethick"></span><span class="ui-button-text">Close</span></button></div><div id="epubDialog" style="display: block;" class="ui-dialog-content ui-widget-content">  <p>We are experimenting with display styles that make it easier to read articles     in PMC.     Our first effort uses eBook readers, which have several "ease of reading"     features already built in.</p>  <p>These PMC articles are best viewed in the <em>iBooks     reader</em>. You may notice problems with the display of certain parts of an article     in other eReaders.</p>  <div class="ui-dialog-buttonpane ui-widget-content ui-helper-clearfix"><button id="cancelEpub" class="ui-state-default ui-corner-all">Cancel</button><button id="downloadEpub" style="float: left" class="ui-state-default ui-corner-all">Download article</button></div>          </div></div><ul class="print-log"><li></li></ul></body></html>